Schedule I [21 CFR 1308.11]
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Source: DEA Office of Diversion Control: Section 1308: Schedules of Controlled Substances
(b)
Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation (for purposes of paragraph (b)(34) only, the term isomer includes the optical and geometric isomers):
Effective 29 May 1987, 52 FR 20070 added (and renumbered subsequent entries):
(1)
9815
Acetyl-alpha-methylfentanyl (N-[1-(1-Methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide)
CA: CDSA Schedule I Section 16 Subsection 1 Acetyl-α-methylfentanyl
UK: MDA Part I Class A Section 1(d) Acetyl-α-methylfentanyl
UN: Narcotics Part 1 Section 1 Acetyl-alpha-methylfentanyl and Section 3 Acetyl-alpha-methylfentanyl
(2)
9601
Acetylmethadol
CA: CDSA Schedule I Section 6 Subsection 1 Acetylmethadol
UK: MDA Part I Class A Section 1(a) Methadyl acetate
UN: Narcotics Part 1 Section 1 Acetylmethadol
Effective 23 Jan 1987, 52 FR 2516 revoked (and renumbered subsequent entries):
Effective 24 Aug 1984, 49 FR 25849 added (and renumbered subsequent entries):
9737
Alfentanil
US: Currently at CSA Schedule II Section c Subsection 1 Alfentanil
(3)
9602
Allylprodine
CA: CDSA Schedule I Section 3 Subsection 1 Allylprodine
UK: MDA Part I Class A Section 1(a) Allylprodine
UN: Narcotics Part 1 Section 1 Allylprodine
(4)
9603
Alphacetylmethadol (except levo-Alphacetylmethadol also known as levo-Alpha-acetylmethadol, Levomethadyl acetate, or LAAM)
Effective 18 Aug 1993, 58 FR 43795 replacement for:
Alphacetylmathadol [sic]
CA: CDSA Schedule I Section 6 Subsection 2 Alphacetylmethadol
UK: MDA Part I Class A Section 1(a) Alphacetylmethadol
UN: Narcotics Part 1 Section 1 Alphacetylmethadol
(5)
9604
Alphameprodine
CA: CDSA Schedule I Section 3 Subsection 2 Alphameprodine
UK: MDA Part I Class A Section 1(a) Alphameprodine
UN: Narcotics Part 1 Section 1 Alphameprodine
(6)
9605
Alphamethadol
CA: CDSA Schedule I Section 6 Subsection 3 Alphamethadol
UK: MDA Part I Class A Section 1(a) Alphamethadol
UN: Narcotics Part 1 Section 1 Alphamethadol
Effective 22 Sep 1981, 46 FR 46799 added (and renumbered subsequent entries):
(7)
9814
Alpha-methylfentanyl (N-[1-(Alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-Methyl-2-phenylethyl)-4-(N-propanilido)piperidine)
CA: CDSA Schedule I Section 16 Subsection 8 α-Methylfentanyl
UK: MDA Part I Class A Section 1(d) α-Methylfentanyl
UN: Narcotics Part 1 Section 1 Alpha-Methylfentanyl and Section 3 Alpha-Methylfentanyl
Effective 29 May 1987, 52 FR 20070 added (and renumbered subsequent entries):
(8)
9832
Alpha-methylthiofentanyl (N-[1-Methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)
CA: CDSA Schedule I Section 16 Subsection 9 α-Methylthiofentanyl
UK: MDA Part I Class A Section 1(d) α-Methylthiofentanyl
UN: Narcotics Part 1 Section 1 Alpha-Methylthiofentanyl and Section 3 Alpha-Methylthiofentanyl
(9)
9606
Benzethidine
CA: CDSA Schedule I Section 3 Subsection 7 Benzethidine
UK: MDA Part I Class A Section 1(a) Benzethidine
UN: Narcotics Part 1 Section 1 Benzethidine
(10)
9607
Betacetylmethadol
CA: CDSA Schedule I Section 6 Subsection 4 Betacetylmethadol
UK: MDA Part I Class A Section 1(a) Betacetylmethadol
UN: Narcotics Part 1 Section 1 Betacetylmethadol
Effective 29 May 1987, 52 FR 20070 added (and renumbered subsequent entries):
(11)
9830
Beta-hydroxyfentanyl (N-[1-(2-Hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide)
CA: CDSA Schedule I Section 16 Subsection 6 β-Hydroxyfentanyl
UK: MDA Part I Class A Section 1(d) β-Hydroxyfentanyl
UN: Narcotics Part 1 Section 1 Beta-Hydroxyfentanyl and Section 3 Beta-Hydroxyfentanyl
Effective 8 Jan 1988, 53 FR 500 added (and renumbered subsequent entries):
(12)
9831
Beta-hydroxy-3-methylfentanyl (N-[1-(2-Hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)
CA: CDSA Schedule I Section 16 Subsection 7 β-Hydroxy-3-methylfentanyl
UK: MDA Part I Class A Section 1(d) β-Hydroxy-3-methylfentanyl
UN: Narcotics Part 1 Section 1 Beta-Hydroxy-3-methylfentanyl and Section 3 Beta-Hydroxy-3-methylfentanyl
(13)
9608
Betameprodine
CA: CDSA Schedule I Section 3 Subsection 5 Betameprodine
UK: MDA Part I Class A Section 1(a) Betameprodine
UN: Narcotics Part 1 Section 1 Betameprodine
(14)
9609
Betamethadol
CA: CDSA Schedule I Section 6 Subsection 5 Betamethadol
UK: MDA Part I Class A Section 1(a) Betamethadol
UN: Narcotics Part 1 Section 1 Betamethadol
(15)
9611
Betaprodine
CA: CDSA Schedule I Section 3 Subsection 6 Betaprodine
UK: MDA Part I Class A Section 1(a) Betaprodine
UN: Narcotics Part 1 Section 1 Betaprodine
(16)
9612
Clonitazene
CA: CDSA Schedule I Section 13 Subsection 1 Clonitazene
UK: MDA Part I Class A Section 1(a) Clonitazene
UN: Narcotics Part 1 Section 1 Clonitazene
(17)
9613
Dextromoramide
CA: CDSA Schedule I Section 9 Subsection 1 Dextromoramide
UK: MDA Part I Class A Section 1(a) Dextromoramide
UN: Narcotics Part 1 Section 1 Dextromoramide
Effective 1 Oct 1976, 41 FR 43401 revoked (and renumbered subsequent entries):
Dextrorphan
(18)
9615
Diampromide
CA: CDSA Schedule I Section 12 Subsection 1 Diampromide
UK: MDA Part I Class A Section 1(a) Diampromide
UN: Narcotics Part 1 Section 1 Diampromide
(19)
9616
Diethylthiambutene
CA: CDSA Schedule I Section 8 Subsection 1 Diethylthiambutene
UK: MDA Part I Class A Section 1(a) Diethylthiambutene
UN: Narcotics Part 1 Section 1 Diethylthiambutene
Effective 1 Jun 1975, 40 FR 19813 added (and renumbered subsequent entries):
(20)
9168
(21)
9617
Dimenoxadol
CA: CDSA Schedule I Section 7 Subsection 1 Dimenoxadol
UK: MDA Part I Class A Section 1(a) Dimenoxadole
UN: Narcotics Part 1 Section 1 Dimenoxadol
(22)
9618
Dimepheptanol
CA: CDSA Schedule I Section 6 Subsection 6 Dimepheptanol
UK: MDA Part I Class A Section 1(a) Dimepheptanol
UN: Narcotics Part 1 Section 1 Dimepheptanol
(23)
9619
Dimethylthiambutene
CA: CDSA Schedule I Section 8 Subsection 2 Dimethylthiambutene
UK: MDA Part I Class A Section 1(a) Dimethylthiambutene
UN: Narcotics Part 1 Section 1 Dimethylthiambutene
(24)
9621
Dioxaphetyl butyrate
CA: CDSA Schedule I Section 7 Subsection 2 Dioxaphetyl butyrate
UK: MDA Part I Class A Section 1(a) Dioxaphetyl butyrate
UN: Narcotics Part 1 Section 1 Dioxaphetyl butyrate
(25)
9622
Dipipanone
CA: CDSA Schedule I Section 5 Subsection 2 Dipipanone
UK: MDA Part I Class A Section 1(a) Dipipanone
UN: Narcotics Part 1 Section 1 Dipipanone
(26)
9623
Ethylmethylthiambutene
CA: CDSA Schedule I Section 8 Subsection 3 Ethylmethylthiambutene
UK: MDA Part I Class A Section 1(a) Ethylmethylthiambutene
UN: Narcotics Part 1 Section 1 Ethylmethylthiambutene
(27)
9624
Etonitazene
CA: CDSA Schedule I Section 13 Subsection 2 Etonitazene
UK: MDA Part I Class A Section 1(a) Etonitazene
UN: Narcotics Part 1 Section 1 Etonitazene
(28)
9625
Etoxeridine
CA: CDSA Schedule I Section 3 Subsection 10 Etoxeridine
UK: MDA Part I Class A Section 1(a) Etoxeridine
UN: Narcotics Part 1 Section 1 Etoxeridine
(29)
9626
Furethidine
CA: CDSA Schedule I Section 3 Subsection 11 Furethidine
UK: MDA Part I Class A Section 1(a) Furethidine
UN: Narcotics Part 1 Section 1 Furethidine
(30)
9627
Hydroxypethidine
CA: CDSA Schedule I Section 3 Subsection 12 Hydroxypethidine
UK: [revoked] MDA Part I Class A Section 1(a) Hydroxypethidine
UN: Narcotics Part 1 Section 1 Hydroxypethidine
(31)
9628
Ketobemidone
CA: CDSA Schedule I Section 3 Subsection 13 Ketobemidone
UK: MDA Part I Class A Section 1(a) Ketobemidone
UN: Narcotics Part 1 Section 1 Ketobemidone and Section 3 Ketobemidone
(32)
9629
Levomoramide
CA: CDSA Schedule I Section 9 Subsection 3 Levomoramide
UK: MDA Part I Class A Section 1(a) Levomoramide
UN: Narcotics Part 1 Section 1 Levomoramide
(33)
9631
Levophenacylmorphan
CA: CDSA Schedule I Section 10 Subsection 5 Levophenacylmorphan
UK: MDA Part I Class A Section 1(a) Levophenacylmorphan
UN: Narcotics Part 1 Section 1 Levophenacylmorphan
Effective 22 Sep 1986, 51 FR 33592 added (and renumbered subsequent entries):
(34)
9813
3-Methylfentanyl (N-[3-Methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide)
CA: CDSA Schedule I Section 16 Subsection 10 3-Methylfentanyl
UK: MDA Part I Class A Section 1(d) 3-Methylfentanyl
UN: Narcotics Part 1 Section 1 3-Methylfentanyl and Section 3 3-Methylfentanyl
Effective 29 May 1987, 52 FR 20070 added (and renumbered subsequent entries):
(35)
9833
3-Methylthiofentanyl (N-[3-Methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)
CA: CDSA Schedule I Section 16 Subsection 11 3-Methylthiofentanyl
UK: MDA Part I Class A Section 1(d) 3-Methylthiofentanyl
UN: Narcotics Part 1 Section 1 3-Methylthiofentanyl and Section 3 3-Methylthiofentanyl
(36)
9632
Morpheridine
CA: CDSA Schedule I Section 3 Subsection 15 Morpheridine
UK: MDA Part I Class A Section 1(a) Morpheridine
UN: Narcotics Part 1 Section 1 Morpheridine
(38)
9633
Noracymethadol
CA: CDSA Schedule I Section 6 Subsection 7 Noracymethadol
UK: MDA Part I Class A Section 1(a) Noracymethadol
UN: Narcotics Part 1 Section 1 Noracymethadol
(39)
9634
Norlevorphanol
CA: CDSA Schedule I Section 10 Subsection 6 Norlevorphanol
UK: MDA Part I Class A Section 1(a) Norlevorphanol
UN: Narcotics Part 1 Section 1 Norlevorphanol
(40)
9635
Normethadone
CA: CDSA Schedule I Section 5 Subsection 5 Normethadone
UK: MDA Part I Class A Section 1(a) Normethadone
UN: Narcotics Part 1 Section 1 Normethadone
(41)
9636
Norpipanone
CA: CDSA Schedule I Section 5 Subsection 6 Norpipanone
UK: MDA Part I Class A Section 1(a) Norpipanone
UN: Narcotics Part 1 Section 1 Norpipanone
Effective 29 May 1987, 52 FR 20070 added (and renumbered subsequent entries):
(42)
9812
Para-fluorofentanyl (N-(4-Fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide)
CA: CDSA Schedule I Section 16 Subsection 4 p-Fluorofentanyl
UK: MDA Part I Class A Section 1(d) p-Fluorofentanyl
UN: Narcotics Part 1 Section 1 Para-Fluorofentanyl and Section 3 Para-Fluorofentanyl
(44)
9637
Phenadoxone
CA: CDSA Schedule I Section 5 Subsection 7 Phenadoxone
UK: MDA Part I Class A Section 1(a) Phenadoxone
UN: Narcotics Part 1 Section 1 Phenadoxone
(45)
9638
Phenampromide
CA: CDSA Schedule I Section 12 Subsection 2 Phenampromide
UK: MDA Part I Class A Section 1(a) Phenampromide
UN: Narcotics Part 1 Section 1 Phenampromide
(46)
9647
Phenomorphan
CA: CDSA Schedule I Section 10 Subsection 7 Phenomorphan
UK: MDA Part I Class A Section 1(a) Phenomorphan
UN: Narcotics Part 1 Section 1 Phenomorphan
(47)
9641
Phenoperidine
CA: CDSA Schedule I Section 3 Subsection 18 Phenoperidine
UK: MDA Part I Class A Section 1(a) Phenoperidine
UN: Narcotics Part 1 Section 1 Phenoperidine
(48)
9642
Piritramide
CA: CDSA Schedule I Section 15 Piritramide
UK: MDA Part I Class A Section 1(a) Piritramide
UN: Narcotics Part 1 Section 1 Piritramide
(49)
9643
Proheptazine
CA: CDSA Schedule I Section 4 Subsection 1 Proheptazine
UK: MDA Part I Class A Section 1(a) Proheptazine
UN: Narcotics Part 1 Section 1 Proheptazine
(50)
9644
Properidine
CA: CDSA Schedule I Section 3 Subsection 20 Properidine
UK: MDA Part I Class A Section 1(a) Properidine
UN: Narcotics Part 1 Section 1 Properidine
(52)
9645
Racemoramide
CA: CDSA Schedule I Section 9 Subsection 4 Racemoramide
UK: MDA Part I Class A Section 1(a) Racemoramide
UN: Narcotics Part 1 Section 1 Racemoramide
Effective 25 May 1984, 49 FR 22074 revoked (and renumbered subsequent entries):
Effective 1 Dec 1980, 45 FR 64571 added:
9740
Sufentanil
US: Currently at CSA Schedule II Section c Subsection 27 Sufentanil
Effective 29 May 1987, 52 FR 20070 added (and renumbered subsequent entries):
(53)
9835
Thiofentanyl (N-Phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide)
CA: CDSA Schedule I Section 16 Subsection 13 Thiofentanyl
UK: MDA Part I Class A Section 1(d) Thiofentanyl
UN: Narcotics Part 1 Section 1 Thiofentanyl and Section 3 Thiofentanyl
(55)
9646
Trimeperidine
CA: CDSA Schedule I Section 3 Subsection 21 Trimeperidine
UK: MDA Part I Class A Section 1(a) Trimeperidine
UN: Narcotics Part 1 Section 1 Trimeperidine
(1)
9319
Acetorphine
CA: CDSA Schedule I Section 1 Subsection 5 Acetorphine
UK: MDA Part I Class A Section 1(a) Acetorphine
UN: Narcotics Part 1 Section 1 Acetorphine and Section 3 Acetorphine
(2)
9051
Acetyldihydrocodeine
CA: CDSA Schedule I Section 1 Subsection 6 Acetyldihydrocodeine
UK: MDA Part II Class B Section 1(a) Acetyldihydrocodeine
UN: Narcotics Part 1 Section 2 Acetyldihydrocodeine and Part 2 Section 1 Acetyldihydrocodeine
(3)
9052
Benzylmorphine
CA: CDSA Schedule I Section 1 Subsection 7 Benzylmorphine
UK: MDA Part I Class A Section 1(a) Benzylmorphine
UN: Narcotics Part 1 Section 1 Benzylmorphine
(7)
9055
Desomorphine
CA: CDSA Schedule I Section 1 Subsection 9 Desomorphine
UK: MDA Part I Class A Section 1(a) Desomorphine
UN: Narcotics Part 1 Section 1 Desomorphine and Section 3 Desomorphine
(8)
9145
Dihydromorphine
CA: CDSA Schedule I Section 1 Subsection 12 Dihydromorphine
UK: MDA Part I Class A Section 1(a) Dihydromorphine
UN: Narcotics Part 1 Section 1 Dihydromorphine
Effective 6 Aug 1973, 38 FR 17717 added:
(9)
9335
Drotebanol
CA: CDSA Schedule I Section 10 Subsection 2 Drotebanol
UK: MDA Part I Class A Section 1(a) Drotebanol
UN: Narcotics Part 1 Section 1 Drotebanol
(11)
9200
Heroin
CA: CDSA Schedule I Section 1 Subsection 10 Diacetylmorphine
UK: MDA Part I Class A Section 1(a) Diamorphine
(12)
9301
Hydromorphinol
CA: CDSA Schedule I Section 1 Subsection 16 Hydromorphinol
UK: MDA Part I Class A Section 1(a) Hydromorphinol
UN: Narcotics Part 1 Section 1 Hydromorphinol
(13)
9302
Methyldesorphine
CA: CDSA Schedule I Section 1 Subsection 18 Methyldesorphine
UK: MDA Part I Class A Section 1(a) Methyldesorphine
UN: Narcotics Part 1 Section 1 Methyldesorphine
(14)
9304
Methyldihydromorphine
CA: CDSA Schedule I Section 1 Subsection 19 Methyldihydromorphine
UK: MDA Part I Class A Section 1(a) Methyldihydromorphine
UN: Narcotics Part 1 Section 1 Methyldihydromorphine
(15)
9305
Morphine methobromide
UK: MDA Part I Class A Section 1(a) Morphine methobromide
UN: Narcotics Part 1 Section 1 Morphine methobromide
(17)
9307
Morphine-N-oxide
CA: CDSA Schedule I Section 1 Subsection 21 Morphine-N-oxide
UK: MDA Part I Class A Section 1(a) Morphine N-oxide
UN: Narcotics Part 1 Section 1 Morphine-N-oxide
(19)
9309
Nicocodeine
CA: CDSA Schedule I Section 1 Subsection 24 Nicocodine
UK: MDA Part II Class B Section 1(a) Nicocodine
UN: Narcotics Part 1 Section 2 Nicocodine and Part 2 Section 1 Nicocodine
(20)
9312
Nicomorphine
CA: CDSA Schedule I Section 1 Subsection 25 Nicomorphine
UK: MDA Part I Class A Section 1(a) Nicomorphine
UN: Narcotics Part 1 Section 1 Nicomorphine
(21)
9313
Normorphine
CA: CDSA Schedule I Section 1 Subsection 27 Normorphine
UK: MDA Part I Class A Section 1(a) Normorphine
UN: Narcotics Part 1 Section 1 Normorphine
(22)
9314
Pholcodine
CA: CDSA Schedule I Section 1 Subsection 30 Pholcodine
UK: MDA Part II Class B Section 1(a) Pholcodine
UN: Narcotics Part 1 Section 2 Pholcodine and Part 2 Section 1 Pholcodine
⇒
PubChem: 5311356; ChemSpider: 4470854; Bluelight: Pholcodine; Drugs Forum: Pholcodine; Wikipedia: Pholcodine
(d)
Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this paragraph only, the term “isomer” includes the optical, position and geometric isomers):
Effective 12 Sep 1994, 59 FR 46757 added:
(1)
7249
Alpha-ethyltryptamine (Etryptamine; Monase; α-Ethyl-1H-indole-3-ethanamine; 3-(2-Aminobutyl)indole; α-ET; AET)
CA: CDSA Schedule III Section 28 Etryptamine
UK: MDA Part I Class A Section 1(a) Etryptamine
UN: Psychotropics Schedule I Etryptamine
Effective 21 Sep 1973, 38 FR 26447 added:
On 2 Jul 1973, 38 FR 17499 proposed to add:
(2)
7391
4-Bromo-2,5-dimethoxyamphetamine (4-Bromo-2,5-dimethoxy-α-methylphenethylamine; 4-Bromo-2,5-DMA)
CA: CDSA Schedule I Section 19 Subsection 14 4-Bromo-2,5-dimethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 15 4-Bromo-2,5-dimethoxyamphetamine
UK: MDA Part I Class A Section 1(a) 4-Bromo-2,5-dimethoxy-α-methylphenethylamine and Section 1(f) 4-Bromo-2,5-dimethoxy-α-methylphenethylamine
UN: Psychotropics Schedule I Brolamfetamine (DOB)
Effective 2 Jun 1995, 60 FR 28718 added:
On 20 Dec 1994, 59 FR 65521 proposed to add:
(3)
7392
4-Bromo-2,5-dimethoxyphenethylamine (2-(4-Bromo-2,5-dimethoxyphenyl)-1-aminoethane; Alpha-desmethyl DOB; 2C-B; Nexus)
CA: CDSA Schedule III Section 24 4-Bromo-2,5-dimethoxybenzeneethanamine
UK: MDA Part I Class A Section 1(c) 4-Bromo-2,5-dimethoxyphenethylamine
UN: Psychotropics Schedule II 2 C-B
Effective 21 Sep 1973, 38 FR 26447 added:
On 31 May 1973, 38 FR 14288 proposed to add:
(4)
7396
2,5-Dimethoxyamphetamine (2,5-Dimethoxy-α-methylphenethylamine; 2,5-DMA)
CA: CDSA Schedule I Section 19 Subsection 5 2,5-Dimethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 6 2,5-Dimethoxyamphetamine
UK: MDA Part I Class A Section 1(c) 2,5-Dimethoxyamphetamine
UN: Psychotropics Schedule I DMA
Effective 16 Feb 1993, 58 FR 4316 added:
(5)
7399
2,5-Dimethoxy-4-ethylamphetamine (DOET)
CA: CDSA Schedule I Section 19 Subsection 13 4-Ethyl-2,5-dimethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 14 4-Ethyl-2,5-dimethoxyamphetamine
UK: MDA Part I Class A Section 1(c) 4-Ethyl-2,5-dimethoxyamphetamine
UN: Psychotropics Schedule I DOET
⇒
PubChem: 27402; ChemSpider: 25499; PiHKAL • info: DOET; Wikipedia: 2,5-Dimethoxy-4-ethylamphetamine
Effective 18 Mar 2004, 69 FR 12794 added (and renumbered subsequent entries):
On 8 Sep 2003, 68 FR 52872 proposed to add (and to renumber subsequent entries):
(6)
7348
2,5-Dimethoxy-4-(n)-propylthiophenenthylamine (2C-T-7), its optical isomers, salts and salts of isomers
Effective 21 Sep 1973, 38 FR 26447 added:
On 2 Jul 1973, 38 FR 17499 proposed to add:
(7)
7411
4-Methoxyamphetamine (4-Methoxy-α-methylphenethylamine; Paramethoxyamphetamine; PMA)
CA: CDSA Schedule I Section 19 Subsection 6 4-Methoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 7 4-Methoxyamphetamine
UK: MDA Part I Class A Section 1(c) 4-Methoxyamphetamine
UN: Psychotropics Schedule I PMA
(8)
7401
5-Methoxy-3,4-methylenedioxyamphetamine
CA: CDSA Schedule I Section 19 Subsection 10 5-Methoxy-3,4-methylenedioxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 11 5-Methoxy-3,4-methylenedioxyamphetamine
UK: MDA Part I Class A Section 1(c) 5-Methoxy-3,4-methylenedioxyamphetamine
UN: Psychotropics Schedule I MMDA
⇒
PubChem: 26175; ChemSpider: 24386; Drugs Forum: MMDA; PiHKAL • info: MMDA; Wikipedia: MMDA (psychedelic)
(9)
7395
4-Methyl-2,5-dimethoxyamphetamine (4-Methyl-2,5-dimethoxy-α-methylphenethylamine; DOM; STP)
CA: CDSA Schedule I Section 19 Subsection 3 4-Methyl-2,5-dimethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 4 4-Methyl-2,5-dimethoxyamphetamine
UK: MDA Part I Class A Section 1(a) 2,5-Dimethoxy-α,4-dimethylphenethylamine and Section 1(f) 2,5-Dimethoxy-α,4-dimethylphenethylamine
UN: Psychotropics Schedule I STP (DOM)
(10)
7400
3,4-Methylenedioxyamphetamine
CA: CDSA Schedule I Section 19 Subsection 4 3,4-Methylenedioxyamphetamine (MDA)
CA: [revoked] CDSA Schedule III Section 1 Subsection 5 3,4-Methylenedioxyamphetamine (MDA)
UK: MDA Part I Class A Section 1(c) 3,4-Methylenedioxyamphetamine
UN: Psychotropics Schedule I Tenamfetamine (MDA)
Effective 23 Mar 1988, 53 FR 5156 added:
Effective 27 Jan 1988, 53 FR 2225 revoked:
Effective 13 Nov 1986, 51 FR 36552 added (and renumbered subsequent entries):
(11)
7405
3,4-Methylenedioxymethamphetamine (MDMA)
[With thanks to Noel at NIH/NCGC for noticing this entry was botched.]
CA: CDSA Schedule I Section 19 Subsection 8 N-Methyl-3,4-methylenedioxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 9 N-Methyl-3,4-methylenedioxyamphetamine
UK: MDA Part I Class A Section 1(c) N-Methyl-3,4-methylenedioxyamphetamine
UN: Psychotropics Schedule I MDMA
Effective 13 Apr 1989, 54 FR 14797 added (and renumbered subsequent entries):
(12)
7404
3,4-Methylenedioxy-N-ethylamphetamine (N-Ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine; N-Ethyl MDA; MDE; MDEA)
CA: CDSA Schedule I Section 19 Subsection 12 N-Ethyl-3,4-methylenedioxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 13 N-Ethyl-3,4-methylenedioxyamphetamine
UK: MDA Part I Class A Section 1(c) N-Ethyl-3,4-methylenedioxyamphetamine
UN: Psychotropics Schedule I MDE (N-Ethyl MDA)
Effective 13 Apr 1989, 54 FR 14797 added (and renumbered subsequent entries):
(13)
7402
N-Hydroxy-3,4-methylenedioxyamphetamine (N-Hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine; N-Hydroxy MDA)
CA: CDSA Schedule I Section 19 Subsection 20 N-Hydroxy-3,4-methylenedioxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 21 N-Hydroxy-3,4-methylenedioxyamphetamine
UK: MDA Part I Class A Section 1(a) N-Hydroxy-tenamphetamine and Section 1(f) N-Hydroxytenamphetamine
UN: Psychotropics Schedule I N-Hydroxy MDA
(14)
7390
3,4,5-Trimethoxyamphetamine
CA: CDSA Schedule I Section 19 Subsection 21 3,4,5-Trimethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 22 3,4,5-Trimethoxyamphetamine
UK: MDA Part I Class A Section 1(c) 3,4,5-Trimethoxyamphetamine
UN: Psychotropics Schedule I TMA
⇒
PubChem: 31016; ChemSpider: 28775; Bluelight: TMA and isomers; Drugs Forum: TMA 2; Erowid: TMA-2 (and other TMAs); PiHKAL • info: TMA; Wikipedia: Trimethoxyamphetamine
Effective 19 Jan 2011, 75 FR 79296 added (and renumbered subsequent entries):
Effective 28 Oct 2009, 74 FR 55502 extended the comment period of the earlier proposal to 27 Nov 2009 from 21 Sept 2009
On 21 Aug 2009, 74 FR 42217 proposed to add (and to renumber subsequent entries):
(15)
7431
5-Methoxy-N,N-dimethyltryptamine (5-Methoxy-3-[2-(dimethylamino)ethyl)]indole; 5-MeO-DMT), its isomers, salts and salts of isomers
On 1 Mar 2012, 77 FR 12508 proposed to add (and to renumber subsequent entries):
(18)
On 1 Mar 2012, 77 FR 12508 proposed to add:
(i)
1-Butyl-3-(1-naphthoyl)indole (JWH-073)
US: Currently at CSA Schedule I Section g Subsection 4 1-Butyl-3-(1-naphthoyl)indole
On 1 Mar 2012, 77 FR 12508 proposed to add:
(ii)
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497)
US: Currently at CSA Schedule I Section g Subsection 1 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
On 1 Mar 2012, 77 FR 12508 proposed to add:
(iii)
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (Cannabicyclohexanol; CP 47,497 C8 homologue)
US: Currently at CSA Schedule I Section g Subsection 2 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
On 1 Mar 2012, 77 FR 12508 proposed to add:
(iv)
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)
US: Currently at CSA Schedule I Section g Subsection 6 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole
On 1 Mar 2012, 77 FR 12508 proposed to add:
(v)
1-Pentyl-3-(1-naphthoyl)indole (JWH-018; AM678)
US: Currently at CSA Schedule I Section g Subsection 3 1-Pentyl-3-(1-naphthoyl)indole
(18)
7434
Diethyltryptamine (N,N-Diethyltryptamine; DET)
CA: CDSA Schedule III Section 6 N,N-Diethyltryptamine
UK: MDA Part I Class A Section 1(a) N,N-Diethyltryptamine
UN: Psychotropics Schedule I DET
(19)
7435
Dimethyltryptamine (DMT)
CA: CDSA Schedule III Section 7 N,N-Dimethyltryptamine
UK: MDA Part I Class A Section 1(a) N,N-Dimethyltryptamine
UN: Psychotropics Schedule I DMT
Effective 29 Sep 2004, 69 FR 58050 added (and renumbered subsequent entries):
(20)
7439
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts and salts of isomers
UK: MDA Part I Class A Section 1(b) 5-Methoxy-N,N-diisopropyltryptamine
⇒
PubChem: 151182; ChemSpider: 133247; Bluelight: 5-MeO-DiPT; Drugs Forum: 5-MeO-DIPT; Erowid: 5-MeO-DIPT; TiHKAL • info: 5-MeO-DIPT; Wikipedia: 5-Methoxy-diisopropyltryptamine
(22)
7315
Lysergic acid diethylamide
CA: CDSA Schedule III Section 5 Lysergic acid diethylamide
UK: MDA Part I Class A Section 1(a) Lysergide
UN: Psychotropics Schedule I (+)-Lysergide (LSD) (LSD-25)
(26)
7415
Peyote
Meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12))
CA: [not controlled] CDSA Schedule III Section 17 Lophophora
⇒
PubChem: 135309929 135330128; Bluelight: Peyote; Drugs Forum: Peyote; Erowid: Peyote; Wikipedia: Peyote
(28)
7484
N-Methyl-3-piperidyl benzilate
CA: CDSA Schedule III Section 8 N-Methyl-3-piperidyl benzilate (LBJ)
(29)
7437
Psilocybin
CA: CDSA Schedule III Section 12 Psilocybin
UK: MDA Part I Class A Section 1(b) Psilocybin
UN: Psychotropics Schedule I Psilocybine
⇒
PubChem: 10624; ChemSpider: 10178; Drugs Forum: 4-H2PO4-DMT; Erowid: Psilocybin & Psilocin; TiHKAL • info: 4-H2PO4-DMT; Wikipedia: Psilocybin
(30)
7438
Psilocyn [sic]
This substance is more commonly spelled Psilocin.
CA: CDSA Schedule III Section 11 Psilocin
UK: MDA Part I Class A Section 1(a) Psilocin
UN: Psychotropics Schedule I Psilocine (Psilotsin)
On 8 Sep 2003, 68 FR 52872 proposed to add (and to renumber subsequent entries):
7494
1-(3-Trifluoromethylphenyl)piperazine (TFMPP)
The proposal to schedule TFMPP was never acted upon. So, once the extended emergency scheduling enacted by 67 FR 59163 expired on 19 Mar 2004, TFMPP was no longer a scheduled substance.
CA: CDSA Schedule III Section 34 Trifluoromethylphenylpiperazine
⇒
PubChem: 4296; ChemSpider: 4145; Bluelight: BZP + TFMPP; Drugs Forum: TFMPP; Erowid: TFMPP; Wikipedia: Trifluoromethylphenylpiperazine
Δ1 cis or trans Tetrahydrocannabinol
Δ6 cis or trans Tetrahydrocannabinol
Δ3,4 cis or trans Tetrahydrocannabinol
(31)
7370
Tetrahydrocannabinols
Meaning Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following:
Meaning Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following:
- Δ1 cis or trans Tetrahydrocannabinol, and their optical isomers
- Δ6 cis or trans Tetrahydrocannabinol, and their optical isomers
- Δ3,4 cis or trans Tetrahydrocannabinol, and its optical isomers
(Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.)
CA: CDSA Schedule II Section 1 Subsection 7 Tetrahydrocannabinol
UK: MDA Part II Class B Section 1(a) Tetrahydrocannabinol
⇒
PubChem: 16078; ChemSpider: 4479482; Bluelight: Tetrahydrocannabinol; Erowid: Cannabis; Wikipedia: TetrahydrocannabinolUN: Psychotropics Schedule I (6aR,10aR)-6a,7,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
UN: Psychotropics Schedule I 7,8,9,10-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
Effective 25 Oct 1978, 43 FR 43295 added:
(32)
7455
Ethylamine analog of Phencyclidine (N-Ethyl-1-phenylcyclohexylamine; (1-Phenylcyclohexyl)ethylamine; N-(1-Phenylcyclohexyl)ethylamine; Cyclohexamine; PCE)
CA: CDSA Schedule III Section 13 N-(1-Phenylcyclohexyl)ethylamine
UK: MDA Part I Class A Section 1(a) Eticyclidine
UN: Psychotropics Schedule I Eticyclidine (PCE)
Effective 25 Oct 1978, 43 FR 43295 added:
(33)
7458
Pyrrolidine analog of Phencyclidine (1-(1-Phenylcyclohexyl)pyrrolidine; PCPy; PHP)
[With thanks to Noel at NIH/NCGC for noticing this entry was botched.]
CA: CDSA Schedule III Section 16 Rolicyclidine
UK: MDA Part I Class A Section 1(a) Rolicyclidine
UN: Psychotropics Schedule I Rolicyclidine (PHP) (PCPY)
⇒
PubChem: 62436; ChemSpider: 56218; Bluelight: PCP analogs; Drugs Forum: PCP analogs; Erowid: Rolicyclidine synthesis; Wikipedia: Rolicyclidine
Effective 11 Aug 1975, 40 FR 28611b added (and renumbered subsequent entries):
On 29 May 1975, 40 FR 23306 proposed to add (and to renumber subsequent entries):
(34)
7470
Thiophene analog of Phencyclidine (1-[1-(2-Thienyl)cyclohexyl]piperidine; 2-Thienyl analog of Phencyclidine; TPCP; TCP)
CA: CDSA Schedule III Section 14 1-[1-(2-Thienyl)cyclohexyl]piperidine
UK: MDA Part I Class A Section 1(a) Tenocyclidine
UN: Psychotropics Schedule I Tenocyclidine (TCP)
⇒
PubChem: 62751; ChemSpider: 56495; Bluelight: PCP analogs; Drugs Forum: Tenocyclidine; Wikipedia: Tenocyclidine![3D rendering of 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine](data:image/png;base64,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 "Click for a 3D rendering of 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine")
On 5 Jul 2011, 76 FR 39039 proposed to add:
(36)
7350
Marihuana extract
UN: Narcotics Part 1 Section 1 Extracts and tinctures of cannabis
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(36)
1248
4-Methylmethcathinone (Mephedrone)
EU: Substances Substances 4-Methylmethcathinone
UK: MDA Part II Class B Section 1(aa) 4-Methylmethcathinone; Mephedrone
⇒
PubChem: 45266826; ChemSpider: 21485694; Bluelight: Mephedrone; Drugs Forum: Mephedrone; Erowid: 4-Methylmethcathinone / Mephedrone; Wikipedia: Mephedrone
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(37)
7535
3,4-Methylenedioxypyrovalerone (MDPV)
CA: CDSA Schedule I Section 17.1 Methylenedioxypyrovalerone
EU: Substances Substances 3,4-Methylenedioxypyrovalerone
UK: MDA Part II Class B Section 1(aa) MDPV
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(38)
7509
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(39)
7508
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(40)
7519
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(41)
7518
![3D rendering of 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine](data:image/png;base64,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 "Click for a 3D rendering of 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine")
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(42)
7585
![3D rendering of 2-[4-(Isopropylthio)-2,5-dimethoxy-phenyl]ethylamine](data:image/png;base64,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 "Click for a 3D rendering of 2-[4-(Isopropylthio)-2,5-dimethoxy-phenyl]ethylamine")
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(43)
7532
2-[4-(Isopropylthio)-2,5-dimethoxy-phenyl]ethylamine (2C-T-4)
UK: MDA Part I Class A Section 1(c) 4-Isopropylthio-2,5-dimethoxyphenethylamine and 4-Isopropylthio-2,5-dimethoxyphenethylamine
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(44)
7517
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)
UK: MDA Part I Class A Section 1(c) 2,5-Dimethoxyphenethylamine
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(46)
7524
Effective 12 Apr 2013, 78 FR 21818 added:
On 17 Oct 2012, 77 FR 63766 proposed to add:
(47)
7540
3,4-Methylenedioxy-N-methylcathinone (Methylone)
In the few months between the proposed and final ruling this section of the schedule has grown by 28 per cent.
On 13 Nov 2015, 80 FR 70649 proposed to add:
(48)
7538
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe)
EU: Substances Substances 2-(4-Iodo-2,5-dimethoxy)-N-(2-methoxybenzyl) phenethylamine
UK: MDA Part I Class A Section 1(f) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
UK: [revoked] MDA Temporary Class Drug Orders 2013 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
See also CSA Schedule I Section h Subsection 4 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
On 13 Nov 2015, 80 FR 70649 proposed to add:
(49)
7537
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe)
UK: MDA Part I Class A Section 1(f) 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
UK: [revoked] MDA Temporary Class Drug Orders 2013 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
See also CSA Schedule I Section h Subsection 5 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
On 13 Nov 2015, 80 FR 70649 proposed to add:
(50)
7536
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe)
UK: MDA Part I Class A Section 1(f) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
UK: [revoked] MDA Temporary Class Drug Orders 2013 2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
See also CSA Schedule I Section h Subsection 6 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(e)
Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
Effective 13 Mar 2000, 65 FR 13235 added:
(1)
2010
Gamma-hydroxybutyric acid (GHB; Gamma-hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic acid; Sodium oxybate; Sodium oxybutyrate)
CA: CDSA Schedule I Section 21 4-Hydroxybutanoic acid
CA: [revoked] CDSA Schedule III Section 26 4-Hydroxybutanoic acid
UK: MDA Part III Class C Section 1(a) 4-Hydroxy-n-butyric acid
UN: Psychotropics Schedule II GHB
UN: [revoked] Psychotropics Schedule IV GHB
See also CSA Schedule III Section c Subsection 6 Gamma-hydroxybutyric acid
⇒
PubChem: 10413; ChemSpider: 9984; Drugs Forum: GHB; Erowid: GHB; Wikipedia: gamma-Hydroxybutyric acid
Effective 10 Jul 1975, 40 FR 28611a added:
On 29 May 1975, 40 FR 23306 proposed to add:
(2)
2572
Mecloqualone
CA: CDSA Schedule III Section 4 Mecloqualone
UK: MDA Part II Class B Section 1(a) Mecloqualone
UN: Psychotropics Schedule II Mecloqualone
Effective 27 Aug 1984, 49 FR 33870 added:
(3)
2565
Methaqualone
CA: CDSA Schedule III Section 3 Methaqualone
UK: MDA Part II Class B Section 1(a) Methaqualone
UN: Psychotropics Schedule II Methaqualone
⇒
PubChem: 6292; ChemSpider: 6055; Bluelight: Methaqualone; Drugs Forum: Methaqualone; Erowid: Methaqualone; Wikipedia: MethaqualoneEffective 20 Aug 1981, 46 FR 37503 added:
(f)
Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
Effective 18 Mar 1994, 59 FR 12828 added (and renumbered subsequent entries):
(1)
1585
Aminorex (Aminoxaphen; 2-Amino-5-phenyl-2-oxazoline; 4,5-Dihydro-5-phenyl-2-oxazolamine)
Effective 6 Aug 2010, 75 FR 47503 corrected the claim made in 68 FR 52872 that BZP is 10 to 20 times more potent than amphetamine. Instead, the converse is now claimed: that BZP is 10 to 20 times less potent than amphetamine.
Effective 6 Aug 2010, 75 FR 47451 corrected the claim made in 68 FR 12794 that BZP is 10 to 20 times more potent than amphetamine. Instead, the converse is now claimed: that BZP is 10 to 20 times less potent than amphetamine.
Effective 18 Mar 2004, 69 FR 12794 added (and renumbered subsequent entries):
On 8 Sep 2003, 68 FR 52872 proposed to add (and to renumber subsequent entries):
(2)
7493
N-Benzylpiperazine (BZP; 1-Benzylpiperazine), its optical isomers, salts and salts of isomers
CA: CDSA Schedule III Section 33 Benzylpiperazine
EU: Substances Substances 1-Benzylpiperazine
UK: MDA Part III Class C Section 1(ca) 1-Benzylpiperazine
Effective 16 Feb 1993, 58 FR 4316 added:
(3)
1235
Cathinone (2-Amino-1-phenyl-1-propanone; Alpha-aminopropiophenone; 2-Aminopropiophenone; Norephedrone)
Effective 20 Aug 1981, 46 FR 37503 added:
(4)
1503
Fenethylline
CA: CDSA Schedule III Section 20 Fenetylline
UK: MDA Part III Class C Section 1(a) Fenethylline
UN: Psychotropics Schedule II Fenetylline
Effective 15 Oct 1993, 58 FR 53404 added (and renumbered subsequent entries):
(5)
1237
Methcathinone (2-(Methylamino)propiophenone; Alpha-(methylamino)propiophenone; 2-(Methylamino)-1-phenylpropan-1-one; Alpha-N-methylaminopropiophenone; Monomethylpropion; Ephedrone; N-Methylcathinone; Methylcathinone; AL-464; AL-422; AL-463; UR1432), its salts, optical isomers and salts of optical isomers
CA: CDSA Schedule III Section 21 2-Methylamino-1-phenyl-1-propanone
UK: MDA Part II Class B Section 1(a) Methcathinone
UN: Psychotropics Schedule I Methcathinone
⇒
PubChem: 1576; ChemSpider: 1519; Bluelight: methcathinone; Drugs Forum: methcathinone; Erowid: Cathinone and methcathinone; Wikipedia: Methcathinone
Effective 13 Apr 1989, 54 FR 14799 added (and renumbered subsequent entries):
(6)
1590
(±)-cis-4-Methylaminorex ((±)-cis-4,5-Dihydro-4-methyl-5-phenyl-2-oxazolamine)
CA: CDSA Schedule III Section 18 4-Methylaminorex
UK: MDA Part I Class A Section 1(a) 4-Methyl-aminorex
UN: Psychotropics Schedule I 4-Methylaminorex
⇒
PubChem: 92196; ChemSpider: 83237; Drugs Forum: 4-MAR; Erowid: 4-Methyl-aminorex; Wikipedia: 4-Methylaminorex
(7)
1475
N-Ethylamphetamine
CA: CDSA Schedule I Section 19 Subsection 2 N-Ethylamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 3 N-Ethylamphetamine
UK: MDA Part III Class C Section 1(a) N-Ethylamphetamine
UN: Psychotropics Schedule IV Etilamfetamine (N-Ethylamphetamine)
Effective 2 Feb 1990, 55 FR 3586 added (and renumbered subsequent entries):
(8)
1480
N,N-Dimethylamphetamine (N,N-Alpha-trimethyl-benzeneethanamine; N,N-Alpha-trimethylphenethylamine)
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(g)
Cannabimimetic Agents. Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(A)
The term ‘cannabimimetic agents’ means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(i)
2-(3-Hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.
UK: MDA Part II Class B Section 1(c) 2-(3-Hydroxycyclohexyl)phenol
3-(1-Naphthoyl)indole
3-(1-Naphthylmethane)indole
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(ii)
3-(1-Naphthoyl)indole or 3-(1-Naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.
CA: CDSA Schedule II Section 2 Subsection 2 3-(1-Naphthoyl)indole
UK: MDA Part II Class B Section 1(c) 3-(1-Naphthoyl)indole
UK: MDA Part II Class B Section 1(c) 1H-Indol-3-yl-(1-naphthyl)methane
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(iii)
3-(1-Naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.
CA: CDSA Schedule II Section 2 Subsection 3 3-(1-Naphthoyl)pyrrole
UK: MDA Part II Class B Section 1(c) 3-(1-Naphthoyl)pyrrole
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(iv)
1-(1-Naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.
UK: MDA Part II Class B Section 1(c) 1-(1-Naphthylmethylene)indene
3-Phenylacetylindole
3-Benzoylindole
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(v)
3-Phenylacetylindole or 3-Benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.
CA: CDSA Schedule II Section 2 Subsection 4 3-Phenylacetylindole
UK: MDA Part II Class B Section 1(c) 3-Phenylacetylindole
CA: CDSA Schedule II Section 2 Subsection 5 3-Benzoylindole
UK: MDA Part II Class B Section 1(c) 3-Benzoylindole
![3D rendering of 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol](data:image/png;base64,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 "Click for a 3D rendering of 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol")
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(1)
7297
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497)
CA: CDSA Schedule II Section 2 Subsection 1 5-(1,1-Dimethylheptyl)-2-(3-hydroxycyclohexyl)phenol
UK: MDA Part II Class B Section 1(c) CP 47,497
⇒
PubChem: 15942731; ChemSpider: 10205286; Drugs Forum: CP 47,497; Erowid: Spice Product; Wikipedia: CP 47,497![3D rendering of 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol](data:image/png;base64,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 "Click for a 3D rendering of 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol")
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(2)
7298
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (Cannabicyclohexanol; CP 47,497 C8 homologue)
UK: MDA Part II Class B Section 1(c) CP 47,497-C8
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(3)
7118
1-Pentyl-3-(1-naphthoyl)indole (JWH-018; AM678)
CA: CDSA Schedule II Section 2 Subsection 2 1-Pentyl-3-(1-naphthoyl)indole
UK: MDA Part II Class B Section 1(c) JWH-018
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(4)
7173
1-Butyl-3-(1-naphthoyl)indole (JWH-073)
CA: CDSA Schedule II Section 2 Subsection 2 1-Butyl-3-(1-naphthoyl)indole
UK: MDA Part II Class B Section 1(c) JWH-073
⇒
PubChem: 10471670; ChemSpider: 8647081; Bluelight: JWH-073; Erowid: Spice Product; Wikipedia: JWH-073
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(5)
7019
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)
CA: CDSA Schedule II Section 2 Subsection 2 1-Hexyl-3-(1-naphthoyl)indole
![3D rendering of 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole](data:image/png;base64,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 "Click for a 3D rendering of 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole")
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(6)
7200
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)
CA: CDSA Schedule II Section 2 Subsection 2 1-(2-Morpholin-4-ylethyl)-3-(1naphthoyl)indole
UK: MDA Part II Class B Section 1(c) JWH-200
⇒
PubChem: 10045570; ChemSpider: 8221134; Drugs Forum: JWH-200; Erowid: Spice Product; Wikipedia: JWH-200
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(7)
6250
![3D rendering of 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole](data:image/png;base64,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 "Click for a 3D rendering of 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole")
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(8)
7081
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)
CA: CDSA Schedule II Section 2 Subsection 2 1-Butyl-3-(4-methoxy-1-naphthoyl)indole
UK: MDA Part II Class B Section 1(c) JWH-081
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(9)
7122
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(10)
7398
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(11)
7201
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(12)
7694
![3D rendering of 1-Pentyl-3-[(4-methoxy)-benzoyl]indole](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAPMAAADXCAIAAABAqfBIAAAACXBIWXMAAC4jAAAuIwF4pT92AAAAHXRFWHRTb2Z0d2FyZQBHUEwgR2hvc3RzY3JpcHQgOC43MQM/aDQAAAsZSURBVHic7d2/jptKFAbw43uvlGKjSLNSFKWFKE26mGIfAPo0XuUJ8CNAmRKq1EyUKk1kv0AkLCUPgLMvEFCqdDFtOm4xEkvstdd/Zhh89vtVu2RjBvwxDNicGTVNQwDs/GO7AQBGINnAE5INPCHZwBOSDTwh2cATkg08IdnAE5INPCHZwBOSDTwh2cATkg08IdnAE5INPCHZwBOSDTwh2cATkg08IdnAE5INPCHZ9tQ1Tad0eUmjEV1e0nRKdW27TXwg2ZbUNbkuCUFFQU1DRUFCkOsi3LqMUG/EjumUhKAk+WthHFNdU5ZZahMrSLYll5dUFOQ4fy2sKvI8Wq0stYkVJNuS0Yju3PPblsOBMM62RAiqqvWFVUVC2GgNQ0i2JZMJSbm+UEqaTGy0hqH/bDfgoUoScl0iojAkx6GqIilJSipL2y1jAn22JUJQWVJdk+fRaESeR3VNZYnRiC64ggSe0Gdb8/PnzzRN218/f/787ds3e83hBsm25sePH3Ect79+/Pjxy5cvFtvDDJINPCHZwBOSDTwh2cATkg08IdnAE5INPCHZwBOSDTwh2cATkg08IdnAE5INPCHZwBOSDTwNK9mLxcJ2EyywuNVVVVWbj9CzMJRkLxYLz/OCIHBd94Hk23Gc169fB0Ggtvrx48fj8bi3tVdVNZ1OXdf1PC+O45pf1bXGtrIsJ5MJEfm+n+e57/tENJlMyrK03TSDyrIMw1Bt9Ww2a38uisL0qlerVRRFQgjHcbIs6/5setV9splstYuJyHGcPM/b5XmeO45DRFEUrVYriy00obvVs9msXd4e1WEYmtvqLMscxxFCdPftarVSh9Z4PO6+EWfNWrKzLBNCCCGSJLnzD5IkUX/AqS+5d6u7ydO76u6Rc+f5sCgKTidMC8ne1iXneb7WYbTdG4O+ZP8TUXe00O3Uj9Yd+XRHO2VZRlG0tmPZnDB7TXZZlqpX8H1/s1dQId7sUdr/daZ9yXHt78bx6KP63oNkWy/enjC3nVuGr6dkbxtSr5nNZts6DPVPawPEgTt9/HrvEGKHPQc223bsnm/ZYPWR7ENHzDv+/owu5DU29c7Lvh2OuBhVrd3c5907Vz3ct9HIbLKPHrTt6DDajvCU07RRhwZxT/scKtuG1PvYcVXTz30bvUwlW8vguNthrL1IeyE/qH19yuBhHzuOal3XnTveOENHrCH6k639hkae5+rDuc0Qm7tHdigtF3x76h7VKnza98O2k+3apzxa1mWI5lqsUkpVqy5JEvVOa3zlNE3rug7DMOlMXFTXdZqmUsqLiwvf9589e6ZxpftL09RxnCRJJn2Vdp/P5+pTccdxlsul2i1Ca5HiNE1VTc0oilRvpdR1HcexlNL3/SRJ+vxSwP40JzsIAnUVoncXK22IVefUPXKqqrq6urq4uHjx4oX29d5rsVhEUZSsTRTWi+vr6+VyOZvNDMVL7XN13GZZps4VynK5vL6+nkwmVjb8fnpPAb7vtyfE1Wpl4m7otvN+d9WmrW0aEdm6lo2iyPf99tckSUyMgLdd8PS5zw9l8Lt+y+WyW0VXF9V5FEVBREEQmFjFvQxt2uniOF4ul9pfVl2V5nle17Xrut2y34N1rvPUqMvT+XzO9evFA6TuJMrNiaMG6VyTrfR2uQYtvTcGzBnKkwcAeiHZwBOSDTwh2cATkg08IdnAE5INPCHZwBOSDTwh2cATkg08IdnAE5INPCHZwBOSDTydd7IXi8VZPN/BSVVVJh7b0e5ck11VlaqpzrCk+VCpR9Zd1z2Lx2oMJttxHBPPvLT7t67rPM+tPDhtaNNOpyqYmXjlNE1VprMsy7LMxCo00/vAsO/7k8nEXAGhbSX/yrJ8+vTp1dVV/7WL1LPGFp9dH4/HRre6rWS0WVXn5cuXb9++NbfqU2hOdlv5XHsBoXurFj1//vzJkyd9VpLv1iKzVQ0sz3ONlbbX7Kg+p6pSPXr0iIyVejvRGVQ/27PSnIlV7zCcImDdA0xXudRulbPd1Su7RYq1rFqXQVes3FGRdUfFStOV5IdZyVtjudRtYd1xCOmdpEGLgVYZbrZP6bJnlWETs1IMf/aFe+fB2W1Hf3HvOapbu2sIO2eIleG3XbI0h48BdE3jdEYz5hw3V8GO/uKgc9SO965nfc/msTsZOy5Zjh4DnF5J/hxnOTvo9LJtAzfLGe/pxFOHFgOagUndJd3sabSMAY57k859oq1727/jjtOJ3YH1s9yAZs1T88l2/1L73mk7/g8fPqglRM3aNX17i3/b2ePsqC55cwhXluWd/YXG2z7dXqmu6xNf7SAPcabTKIrevHmjfiZqHKfpHjVtss90Tq077dkHG7rto172/fv3bWuaMGyEaIgaIZowbAycDx/o7NS/fv1SPxA1ed44zu2+HcBU9KZYvFXaNM3Xr1+bpmlWq0aIJooatZaybKKoEUJ7uO2/jd2rxjzP1c+93VZTOZ5MbsckjJOtWPx4q2maJgzXx39N00RRE4Z61zOUt7G9W9TzGEDluCwbIRr14QP7ZDd/ny37vu0jRLPZZ6k3QCvN89ScaLFYdGdC6cFoRGoHpCnN51QUt0vYq6oqTVPVeRv6huAdtu1f3ft9WMnuX3d/eh75PqXpQ0m2HZeXVBTkOH8trCryPFqtNK7nXJ88MCFJCA/oGDeZ0OaDC1KS7u+7o8/+q4eeTklK9Nkm1TW5LoUhhSE5DlUVSUlSUlmS1hHRQ++z10KcZYi1YUJQWVJdk+fRaESeR3WtPdaEPlv5/fv3zc1NzxevYNRD77OVm5ubIAhst+Jh+f79u9F9jmSDHavVarFYmHt9JBt4QrKBJyQbeEKygSckG3hCsoEnJBt4QrKBJyQbeEKygSckG3hCsoEnJBt4QrKBJyQbeEKyb8VxbLsJoM2/7969s90G+xzH+fPnT5qmnz59evXqlbNWMwAMUBVOzD2hh+cgb1VVFcfxfD73fV+VCLPdIjgeRiO31DQreZ5XVeW6bhzHmEb1fKHPvluapmre6yRJVH1eOC/os+8WRZGaUmg6nQZBYPRZVDAByd5KVa1XU/QGQTCdTquqst0o2BdGI3uZz+dq2B2GoZWZ3uFQSPa+6rpO01RKqfryie4Ki6AXRiP7agcn4/H4+vo6CAIMToYMyT5Me2ewrmvcGRwyjEaOJ6VUH8jjzuAAoc8+npo0Vd0ZTFFTfmD+s92A86YG38vlEmOSoUGfDTwh2cATkg08IdnAE5INPCHZwBOSDTwh2cATkg08IdnAE5INPCHZwBOSDTwh2cATkg08IdnAE5INPCHZwBOSDTwh2cATkg08IdnAE6oyaCCEkFISURRFapIKsA59tgaz2SwMQyml53nz+dx2c4AIydZFFbP0fV8Vs1wul7Zb9NAh2do4jpNlWZ7nROR53nQ6ReEoi1Cx0ggpZZqmqCRvEZJtCirJ24XRiCltJXkMvq1Ass3C4NsWjEb601aSj6IoiiLbzWEOye6VGnynaar6cnOzjgNGI71Sg++yLMfjcRAEmMbJHCTbAkzj1AMk2xrf94uiyLJMSqm+dgIaIdmWhWE4Ho/RZ2uHZANPSDbwhGQDT0g28IRkA09INvCEZANPSDbwhGQDT0g28IRkA09INvCEZANPSDbwhGQDT0g28IRkA09INvCEZANPSDbwhGQDT0g28IRk2yeEwOw22qGuH/CEPht4QrKBJyQbeEKygSckG3hCsoEnJBt4QrKBJyQbeEKygSckG3hCsoEnJBt4QrKBJyQbeEKygSckG3hCsoEnJBt4QrKBp/8Bk2knrg0YlNAAAAAASUVORK5CYII= "Click for a 3D rendering of 1-Pentyl-3-[(4-methoxy)-benzoyl]indole")
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(13)
7104
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(14)
7008
Effective 4 Jan 2013, 78 FR 664 finalized the prior interim scheduling:
Effective 9 Jul 2012, S. 3187, 112 Cong., 2nd Sess. added:
(15)
7203
On 14 May 2015, 80 FR 27611 proposed to add:
(16)
7144
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone (UR-144)
CA: CDSA Schedule II Section 2 Subsection 6 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)-methanone
UK: MDA Part II Class B Section 1(c) UR-144
See also CSA Schedule I Section h Subsection 1 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone
methanone](data:image/png;base64,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 "Click for a 3D rendering of [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone")
On 14 May 2015, 80 FR 27611 proposed to add:
(17)
7011
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-Fluoro-UR-144; XLR11)
CA: CDSA Schedule II Section 2 Subsection 6 [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone
UK: MDA Part II Class B Section 1(c) XLR11
See also CSA Schedule I Section h Subsection 2 [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone
On 14 May 2015, 80 FR 27611 proposed to add:
(18)
7048
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA; AKB48)
CA: CDSA Schedule II Section 2 Subsection 8 N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide
See also CSA Schedule I Section h Subsection 3 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide
⇒
PubChem: 57404063; ChemSpider: 28189076; Bluelight: AKB48; Drugs Forum: AKB48; Wikipedia: AKB48 (drug)Effective 4 Jan 2013, 78 FR 664 renumbered:
Effective 25 Apr 1985, 50 FR 11690 added:
(h)
Temporary listing of substances subject to emergency scheduling. Any material, compound, mixture or preparation which contains any quantity of the following substances:
Effective 22 Sep 1986, 51 FR 33592 revoked (and renumbered subsequent entries):
Effective 25 Apr 1986, 51 FR 15474 extended, for six months’ duration, the prior emergency scheduling:
Effective 25 Apr 1985, 50 FR 11690 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-[3-Methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide (3-Methylfentanyl) its optical and geometric isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 34 3-Methylfentanyl
Effective 13 Nov 1986, 51 FR 36552 revoked (and renumbered subsequent entries):
Effective 1 Jul 1986, 51 FR 21911 extended, for six months’ duration, the prior emergency scheduling:
Effective 1 Jul 1985, 50 FR 23118 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
3,4-Methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section d Subsection 11 3,4-Methylenedioxymethamphetamine
Effective 23 Jan 1987, 52 FR 2515 revoked (and renumbered subsequent entries):
Effective 12 Aug 1986, 51 FR 28695 extended, for six months’ duration, the prior emergency scheduling:
Effective 12 Aug 1985, 50 FR 28098 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
1-Methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 37 MPPP
Effective 23 Jan 1987, 52 FR 2515 revoked (and renumbered subsequent entries):
Effective 12 Aug 1986, 51 FR 28695 extended, for six months’ duration, the prior emergency scheduling:
Effective 12 Aug 1985, 50 FR 28098 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
1-(2-Phenethyl)-4-phenyl-4-acetoxypiperidine (PEPAP), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 43 PEPAP
Effective 29 May 1987, 52 FR 20070 revoked (and renumbered subsequent entries):
Effective 29 Nov 1986, 51 FR 42834 extended, for six months’ duration, the prior emergency scheduling:
Effective 29 Nov 1985, 50 FR 43698 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-[1-(1-Methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide (Acetyl-alpha-methylfentanyl), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 1 Acetyl-alpha-methylfentanyl
Effective 29 May 1987, 52 FR 20070 revoked (and renumbered subsequent entries):
Effective 29 Nov 1986, 51 FR 42834 extended, for six months’ duration, the prior emergency scheduling:
Effective 29 Nov 1985, 50 FR 43698 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-[1-Methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide (Alpha-methylthiofentanyl), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 8 Alpha-methylthiofentanyl
Effective 4 Jan 2013, 78 FR 664 revoked:
Effective 29 Feb 2012, 77 FR 12201 extended, for six months’ duration, the prior emergency scheduling:
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497), its optical, positional, and geometric isomers, salts and salts of isomers
Effective 1 Mar 2011, 76 FR 11075 replacement, for one year’s duration, via the emergency scheduling provision of 21 USC 811(h), for:
On 24 Nov 2010, 75 FR 71635 proposed replacement, for one year’s duration, via the emergency scheduling provision of 21 USC 811(h), for:
[Reserved]
Effective 29 Jun 2010, 75 FR 37300 replacement for:
Effective 29 May 1987, 52 FR 20070 renumbered:
Effective 29 Nov 1985, 50 FR 43698 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-[1-Benzyl-4-piperidyl]-N-phenylpropanamide (Benzylfentanyl) its optical and geometric isomers, salts and salts of isomers
This substance remained “scheduled” even though the legal authorization that placed it here (50 FR 43698) had expired decades earlier. After a quarter of a century, 75 FR 37300 ultimately banishes it.
Effective 13 Jan 2011, 76 FR 2287 corrected the prior notice of proposed scheduling, 75 FR 71635, by striking out parts addressing the Regulatory Flexibility Act and the Congressional Review Act on the grounds that neither Act applies to the proposal and are therefore immaterial.
While 75 FR 71635 proposed to add only five substances to Schedule I, final rule 76 FR 11075 casts the net rather wider, scheduling the original five and “…the optical, positional, and geometric isomers, salts and salts of isomers” of each. The final rule is silent about this incongruity.
US: Currently at CSA Schedule I Section g Subsection 1 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
Effective 29 May 1987, 52 FR 20070 revoked (and renumbered subsequent entries):
Effective 29 Nov 1986, 51 FR 42834 extended, for six months’ duration, the prior emergency scheduling:
Effective 29 Nov 1985, 50 FR 43698 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-[1-(2-Hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide (Beta-hydroxyfentanyl), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 11 Beta-hydroxyfentanyl
Effective 8 Jan 1988, 53 FR 500 revoked (and renumbered subsequent entries):
Effective 29 Nov 1986, 51 FR 42834 extended, for six months’ duration, the prior emergency scheduling:
Effective 29 Nov 1985, 50 FR 43698 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-[1-(2-Hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide (Beta-hydroxy-3-methylfentanyl), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 12 Beta-hydroxy-3-methylfentanyl
Effective 29 May 1987, 52 FR 20070 revoked (and renumbered subsequent entries):
Effective 29 Nov 1986, 51 FR 42834 extended, for six months’ duration, the prior emergency scheduling:
Effective 29 Nov 1985, 50 FR 43698 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-[3-Methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide (3-Methylthiofentanyl), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 35 3-Methylthiofentanyl
Effective 4 Jan 2013, 78 FR 664 revoked:
Effective 29 Feb 2012, 77 FR 12201 extended, for six months’ duration, the prior emergency scheduling:
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (Cannabicyclohexanol; CP 47,497 C8 homologue), its optical, positional, and geometric isomers, salts and salts of isomers
Effective 1 Mar 2011, 76 FR 11075 replacement, for one year’s duration, via the emergency scheduling provision of 21 USC 811(h), for:
On 24 Nov 2010, 75 FR 71635 proposed replacement, for one year’s duration, via the emergency scheduling provision of 21 USC 811(h), for:
[Reserved]
Effective 29 Jun 2010, 75 FR 37300 replacement for:
Effective 29 May 1987, 52 FR 20070 renumbered:
Effective 29 Nov 1985, 50 FR 43698 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-[1-(2-Thienyl)methyl-4-piperidyl]-N-phenylpropanamide (Thenylfentanyl) its optical and geometric isomers, salts and salts of isomers
This substance remained “scheduled” even though the legal authorization that placed it here (50 FR 43698) had expired decades earlier. After a quarter of a century, 75 FR 37300 ultimately banishes it.
Effective 13 Jan 2011, 76 FR 2287 corrected the prior notice of proposed scheduling, 75 FR 71635, by striking out parts addressing the Regulatory Flexibility Act and the Congressional Review Act on the grounds that neither Act applies to the proposal and are therefore immaterial.
While 75 FR 71635 proposed to add only five substances to Schedule I, final rule 76 FR 11075 casts the net rather wider, scheduling the original five and “…the optical, positional, and geometric isomers, salts and salts of isomers” of each. The final rule is silent about this incongruity.
Effective 29 May 1987, 52 FR 20070 revoked (and renumbered subsequent entries):
Effective 29 Nov 1986, 51 FR 42834 extended, for six months’ duration, the prior emergency scheduling:
Effective 29 Nov 1985, 50 FR 43698 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-Phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide (Thiofentanyl), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 53 Thiofentanyl
Effective 29 May 1987, 52 FR 20070 revoked (and renumbered subsequent entries):
Effective 10 Mar 1987, 52 FR 7270 extended, for six months’ duration, the prior emergency scheduling:
Effective 10 Mar 1986, 51 FR 4722 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-(4-Fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide (Para-fluorofentanyl), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section b Subsection 42 Para-fluorofentanyl
Effective 13 Apr 1989, 54 FR 14797 revoked (and renumbered subsequent entries):
Effective 13 Oct 1988, 53 FR 40061 extended, for six months’ duration, the prior emergency scheduling:
Effective 15 Oct 1987, 52 FR 38225 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
3,4-Methylenedioxy-N-ethylamphetamine (N-Ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine; N-Ethyl MDA; MDE; MDEA)
US: Currently at CSA Schedule I Section d Subsection 12 3,4-Methylenedioxy-N-ethylamphetamine
Effective 13 Apr 1989, 54 FR 14797 revoked (and renumbered subsequent entries):
Effective 13 Oct 1988, 53 FR 40061 extended, for six months’ duration, the prior emergency scheduling:
Effective 15 Oct 1987, 52 FR 38225 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-Hydroxy-3,4-methylenedioxyamphetamine (N-Hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine; N-Hydroxy MDA)
US: Currently at CSA Schedule I Section d Subsection 13 N-Hydroxy-3,4-methylenedioxyamphetamine
Effective 13 Apr 1989, 54 FR 14797 revoked (and renumbered subsequent entries):
Effective 13 Oct 1988, 53 FR 40061 extended, for six months’ duration, the prior emergency scheduling:
Effective 15 Oct 1987, 52 FR 38225 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
4-Methylaminorex (4,5-Dihydro-4-methyl-5-phenyl-2-oxazolamine)
US: Currently at CSA Schedule I Section f Subsection 6 (±)-cis-4-Methylaminorex
Effective 2 Feb 1990, 55 FR 3586 revoked (and renumbered subsequent entries):
Effective 2 Aug 1989, 54 FR 31815 extended, for six months’ duration, the prior emergency scheduling:
Effective 3 Aug 1988, 53 FR 29232 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N,N-Dimethylamphetamine (N,N-Alpha-trimethyl-benzeneethanamine; N,N-Alpha-trimethylphenethylamine), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section f Subsection 8 N,N-Dimethylamphetamine
Effective 15 Oct 1993, 58 FR 53404 revoked (and renumbered subsequent entries):
Effective 1 May 1993, 58 FR 25934 extended, for six months’ duration, the prior emergency scheduling:
Effective 1 May 1992, 57 FR 18824 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Methcathinone (2-(Methylamino)propiophenone; Alpha-(methylamino)propiophenone; 2-(Methylamino)-1-phenylpropan-1-one; Alpha-N-methylaminopropiophenone; Monomethylpropion; Ephedrone; N-Methylcathinone; Methylcathinone; AL-464; AL-422; AL-463; UR1432), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section f Subsection 5 Methcathinone
Effective 18 Mar 1994, 59 FR 12828 revoked (and renumbered subsequent entries):
Effective 21 Sep 1993, 58 FR 44611 extended, for six months’ duration, the prior emergency scheduling:
Effective 21 Sep 1992, 57 FR 43399 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Aminorex (Aminoxaphen; 2-Amino-5-phenyl-2-oxazoline; 4,5-Dihydro-5-phenyl-2-oxazolamine), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section f Subsection 1 Aminorex
Effective 12 Sep 1994, 59 FR 46757 revoked (and renumbered subsequent entries):
Effective 12 Mar 1994, 59 FR 10720 extended, for six months’ duration, the prior emergency scheduling:
Effective 12 Mar 1993, 58 FR 13533 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Alpha-ethyltryptamine (Etryptamine; Monase; ɑ-Ethyl-1H-indole-3-ethanamine; 3-(2-Aminobutyl)indole; ɑ-ET; AET), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section d Subsection 1 Alpha-ethyltryptamine
Effective 6 Jan 1995, 59 FR 65710 extended, for six months’ duration, the prior emergency scheduling:
Effective 2 Jun 1995, 60 FR 28718 revoked:
Effective 6 Jan 1994, 59 FR 671 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
4-Bromo-2,5-dimethoxyphenethylamine (2-(4-Bromo-2,5-dimethoxyphenyl)-1-aminoethane; Alpha-desmethyl DOB; 2C-B; Nexus), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section d Subsection 3 4-Bromo-2,5-dimethoxyphenethylamine
Effective 18 Mar 2004, 69 FR 12794 revoked:
Effective 20 Sep 2003, 68 FR 53289 extended, for six months’ duration, the prior emergency scheduling:
Effective 20 Sep 2002, 67 FR 59161 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
N-Benzylpiperazine (BZP; 1-Benzylpiperazine), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section f Subsection 2 N-Benzylpiperazine
Effective 18 Mar 2004, 69 FR 12794 revoked (and renumbered subsequent entries):
Effective 20 Sep 2003, 68 FR 53289 extended, for six months’ duration, the prior emergency scheduling:
Effective 20 Sep 2002, 67 FR 59161 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
1-(3-Trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts and salts of isomers
Effective 18 Mar 2004, 69 FR 12794 revoked (and renumbered subsequent entries):
Effective 20 Sep 2003, 68 FR 53289 extended, for six months’ duration, the prior emergency scheduling:
Effective 20 Sep 2002, 67 FR 59163 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
2,5-Dimethoxy-4-(n)-propylthiophenenthylamine (2C-T-7), its optical isomers, salts and salts of isomers
US: Currently at CSA Schedule I Section d Subsection 6 2,5-Dimethoxy-4-(n)-propylthiophenenthylamine
Effective 29 Sep 2004, 69 FR 58050 revoked:
Effective 1 Apr 2004, 69 FR 17034 extended, for six months’ duration, the prior emergency scheduling:
Effective 4 Apr 2003, 68 FR 16427 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Alpha-methyltryptamine (AMT), its isomers, salts, and salts of isomers
US: Currently at CSA Schedule I Section d Subsection 16 Alpha-methyltryptamine
Effective 29 Sep 2004, 69 FR 58050 revoked:
Effective 1 Apr 2004, 69 FR 17034 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Effective 4 Apr 2003, 68 FR 16427 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts, and salts of isomers
US: Currently at CSA Schedule I Section d Subsection 20 5-Methoxy-N,N-diisopropyltryptamine
Effective 4 Jan 2013, 78 FR 664 revoked:
Effective 29 Feb 2012, 77 FR 12201 extended, for six months’ duration, the prior emergency scheduling:
Effective 1 Mar 2011, 76 FR 11075 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Effective 13 Jan 2011, 76 FR 2287 corrected the prior notice of proposed scheduling, 75 FR 71635, by striking out parts addressing the Regulatory Flexibility Act and the Congressional Review Act on the grounds that neither Act applies to the proposal and are therefore immaterial.
On 24 Nov 2010, 75 FR 71635 proposed to add, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
1-Butyl-3-(1-naphthoyl)indole (JWH-073), its optical, positional, and geometric isomers, salts and salts of isomers
While 75 FR 71635 proposed to add only five substances to Schedule I, final rule 76 FR 11075 casts the net rather wider, scheduling the original five and “…the optical, positional, and geometric isomers, salts and salts of isomers” of each. The final rule is silent about this incongruity.
US: Currently at CSA Schedule I Section g Subsection 4 1-Butyl-3-(1-naphthoyl)indole
Effective 4 Jan 2013, 78 FR 664 revoked:
Effective 29 Feb 2012, 77 FR 12201 extended, for six months’ duration, the prior emergency scheduling:
Effective 1 Mar 2011, 76 FR 11075 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Effective 13 Jan 2011, 76 FR 2287 corrected the prior notice of proposed scheduling, 75 FR 71635, by striking out parts addressing the Regulatory Flexibility Act and the Congressional Review Act on the grounds that neither Act applies to the proposal and are therefore immaterial.
On 24 Nov 2010, 75 FR 71635 proposed to add, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200), its optical, positional, and geometric isomers, salts and salts of isomers
While 75 FR 71635 proposed to add only five substances to Schedule I, final rule 76 FR 11075 casts the net rather wider, scheduling the original five and “…the optical, positional, and geometric isomers, salts and salts of isomers” of each. The final rule is silent about this incongruity.
US: Currently at CSA Schedule I Section g Subsection 6 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole
Effective 4 Jan 2013, 78 FR 664 revoked:
Effective 29 Feb 2012, 77 FR 12201 extended, for six months’ duration, the prior emergency scheduling:
Effective 1 Mar 2011, 76 FR 11075 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Effective 13 Jan 2011, 76 FR 2287 corrected the prior notice of proposed scheduling, 75 FR 71635, by striking out parts addressing the Regulatory Flexibility Act and the Congressional Review Act on the grounds that neither Act applies to the proposal and are therefore immaterial.
On 24 Nov 2010, 75 FR 71635 proposed to add, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
1-Pentyl-3-(1-naphthoyl)indole (JWH-018), its optical, positional, and geometric isomers, salts and salts of isomers
While 75 FR 71635 proposed to add only five substances to Schedule I, final rule 76 FR 11075 casts the net rather wider, scheduling the original five and “…the optical, positional, and geometric isomers, salts and salts of isomers” of each. The final rule is silent about this incongruity.
US: Currently at CSA Schedule I Section g Subsection 3 1-Pentyl-3-(1-naphthoyl)indole
Effective 4 Jan 2013, 78 FR 664 revoked:
Effective 21 Oct 2011, 76 FR 65371 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 8 Sep 2011, 76 FR 55616 proposed to add, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
4-Methyl-N-methylcathinone (Mephedrone)
US: Currently at CSA Schedule I Section d Subsection 36 4-Methylmethcathinone
Effective 20 Mar 2015, 80 FR 14842 revoked:
Effective 4 Jan 2013, 78 FR 664 renumbered:
Effective 18 Oct 2012, 77 FR 64032 extended, for six months’ duration, the prior emergency scheduling:
Effective 21 Oct 2011, 76 FR 65371 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 8 Sep 2011, 76 FR 55616 proposed to add, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
3,4-Methylenedioxy-N-methylcathinone (Methylone)
US: Currently at CSA Schedule I Section d Subsection 47 3,4-Methylenedioxy-N-methylcathinone
Effective 4 Jan 2013, 78 FR 664 revoked:
Effective 21 Oct 2011, 76 FR 65371 added, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 8 Sep 2011, 76 FR 55616 proposed to add, for one years’ duration, via the emergency scheduling provision of 21 USC 811(h):
3,4-Methylenedioxypyrovalerone (MDPV)
US: Currently at CSA Schedule I Section d Subsection 37 3,4-Methylenedioxypyrovalerone
Effective 15 May 2015, 80 FR 27854 extended, for one years’ duration, the prior emergency scheduling:
On 14 May 2015, 80 FR 27611 proposed to revoke (and to renumber subsequent entries:)
Effective 20 Mar 2015, 80 FR 14842 renumbered:
(1)
7144
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone (UR-144; 1-Pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole), its optical, positional, and geometric isomers, salts and salts of isomers
Effective 16 May 2013, 78 FR 28735 replacement, for two year’s duration, via the emergency scheduling provision of 21 USC 811(h), for:
1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144; 1-Pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole), its optical, positional, and geometric isomers, salts and salts of isomers
On 12 Apr 2013, 78 FR 21858 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Note: The name in the proposed rule is incorrect—it ought to begin with a left parenthethis. This error is corrected in the final rule.
CA: CDSA Schedule II Section 2 Subsection 6 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)-methanone
UK: MDA Part II Class B Section 1(c) UR-144
See also CSA Schedule I Section g Subsection 16 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone
Effective 15 May 2015, 80 FR 27854 extended, for one years’ duration, the prior emergency scheduling:
On 14 May 2015, 80 FR 27611 proposed to revoke (and to renumber subsequent entries:)
Effective 20 Mar 2015, 80 FR 14842 renumbered:
(2)
7011
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-Fluoro-UR-144; 5-F-UR-144; XLR11; 1-(5-Fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole), its optical, positional, and geometric isomers, salts and salts of isomers
Effective 16 May 2013, 78 FR 28735 replacement, for two year’s duration, via the emergency scheduling provision of 21 USC 811(h), for:
1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-Fluoro-UR-144; 5-F-UR-144; XLR11; 1-(5-Fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole), its optical, positional, and geometric isomers, salts and salts of isomers
On 12 Apr 2013, 78 FR 21858 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Note: The name in the proposed rule is incorrect—it ought to begin with a left square bracket, and the hyphen in “Fluoro-pentyl” appears superfluous. The first mistake is corrected in the final rule.
CA: CDSA Schedule II Section 2 Subsection 6 [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone
UK: MDA Part II Class B Section 1(c) XLR11
See also CSA Schedule I Section g Subsection 17 [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone
Effective 15 May 2015, 80 FR 27854 extended, for one years’ duration, the prior emergency scheduling:
On 14 May 2015, 80 FR 27611 proposed to revoke (and to renumber subsequent entries:)
Effective 20 Mar 2015, 80 FR 14842 renumbered:
(3)
7048
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA; AKB48), its optical, positional, and geometric isomers, salts and salts of isomers
Effective 16 May 2013, 78 FR 28735 replacement, for two year’s duration, via the emergency scheduling provision of 21 USC 811(h), for:
N-Adamantyl-1-pentyl-1H-indazole-3-carboxamide (APINACA; AKB48), its optical, positional, and geometric isomers, salts and salts of isomers
On 12 Apr 2013, 78 FR 21858 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
Note: There is a subtle change in the name between the proposed and final rules. While it might be argued the proposed rule describes both the 1- and 2-adamantyl isomers, the final rule specifically names only the former.
CA: CDSA Schedule II Section 2 Subsection 8 N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide
See also CSA Schedule I Section g Subsection 18 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide
⇒
PubChem: 57404063; ChemSpider: 28189076; Bluelight: AKB48; Drugs Forum: AKB48; Wikipedia: AKB48 (drug)
On 13 Nov 2015, 80 FR 70649 proposed to revoke:
Effective 13 Nov 2015, 80 FR 70657 extended, for one years’ duration, the prior emergency scheduling:
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 15 Nov 2013, 78 FR 68716 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 10 Oct 2013, 78 FR 61991 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(4)
7538
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5), its optical, positional, and geometric isomers, salts and salts of isomers
EU: Substances Substances 2-(4-Iodo-2,5-dimethoxy)-N-(2-methoxybenzyl) phenethylamine
UK: MDA Part I Class A Section 1(f) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
UK: [revoked] MDA Temporary Class Drug Orders 2013 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
See also CSA Schedule I Section d Subsection 48 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
On 13 Nov 2015, 80 FR 70649 proposed to revoke:
Effective 13 Nov 2015, 80 FR 70657 extended, for one years’ duration, the prior emergency scheduling:
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 15 Nov 2013, 78 FR 68716 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 10 Oct 2013, 78 FR 61991 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(5)
7537
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82), its optical, positional, and geometric isomers, salts and salts of isomers
UK: MDA Part I Class A Section 1(f) 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
UK: [revoked] MDA Temporary Class Drug Orders 2013 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
See also CSA Schedule I Section d Subsection 49 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
On 13 Nov 2015, 80 FR 70649 proposed to revoke:
Effective 13 Nov 2015, 80 FR 70657 extended, for one years’ duration, the prior emergency scheduling:
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 15 Nov 2013, 78 FR 68716 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 10 Oct 2013, 78 FR 61991 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(6)
7536
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36), its optical, positional, and geometric isomers, salts and salts of isomers
UK: MDA Part I Class A Section 1(f) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
UK: [revoked] MDA Temporary Class Drug Orders 2013 2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
See also CSA Schedule I Section d Subsection 50 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 10 Feb 2014, 79 FR 7577 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 10 Jan 2014, 79 FR 1776 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(7)
7222
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC), its optical, positional, and geometric isomers, salts and salts of isomers
CA: CDSA Schedule II Section 2 Subsection 7 1-Pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid
Effective 5 Feb 2016, 81 FR 6175 extended, for one years’ duration, the prior emergency scheduling:
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 10 Feb 2014, 79 FR 7577 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 10 Jan 2014, 79 FR 1776 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(8)
7225
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-Fluoro-PB-22; 5F-PB-22), its optical, positional, and geometric isomers, salts and salts of isomers
CA: CDSA Schedule II Section 2 Subsection 7 1-(5-Fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 10 Feb 2014, 79 FR 7577 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 10 Jan 2014, 79 FR 1776 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(9)
7012
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA), its optical, positional, and geometric isomers, salts and salts of isomers
CA: CDSA Schedule II Section 2 Subsection 8 N-(1-(Aminocarbonyl)-2-methylpropyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 10 Feb 2014, 79 FR 7577 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 10 Jan 2014, 79 FR 1776 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(10)
7035
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(11)
1249
4-Methyl-N-ethylcathinone (4-MEC; 2-(Ethylamino)-1-(4-methylphenyl)propan-1-one), its optical, positional, and geometric isomers, salts and salts of isomers
⇒
PubChem: 52988259; ChemSpider: 25630091; Drugs Forum: (4-MEC); Erowid: 4-Methylethcathinone (4-MEC); Wikipedia: 4-Methylethcathinone
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(12)
7498
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP; MePPP; 4-Methyl-α-pyrrolidinopropiophenone; 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one), its optical, positional, and geometric isomers, salts and salts of isomers
Strictly speaking, the hyphen between (pyrrolidin-1-yl) and propan-1-one is syntactically incorrect if semantically innocuous.
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(13)
7545
alpha-Pyrrolidinopentiophenone (α-PVP; α-Pyrrolidinopentiophenone; 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one), its optical, positional, and geometric isomers, salts and salts of isomers
Note to hardcore IUPAC junkies: The name given for this substance, like many latter-day cathinones, is a real dog’s breakfast. is not a valid IUPAC name and I suspect never was. I’m guessing it is a recent invention, what linguists call a “back-formation,” patterned after the valid IUPAC name .
derives from the older, now deprecated name for propanoic acid, . It is easy to see how might follow as the name for the four-carbon homologue. In fact is the correct name, derived from , the deprecated name for butanoic acid.
Similarly, is also incorrect. The deprecated name for the five-carbon homologue (pentanoic acid) is , from which derives the correct name . The trivial name pyrovalerone is a contraction of the deprecated (but still valid) name %CE%B1-pyrrolidino-p-methylvalerophenone.
I am indebted to coder extraordinaire Daniel Lowe and his Open Parser for Systematic IUPAC nomenclature (OPSIN), which makes exploring IUPAC nomenclature if not fun, entertaining at least.
⇒
PubChem: 11148955; ChemSpider: 9324063; Drugs Forum: α-PVP; Wikipedia: alpha-Pyrrolidinopentiophenone
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(14)
7541
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(15)
1246
Pentedrone (α-Methylaminovalerophenone; 2-(Methylamino)-1-phenylpentan-1-one), its optical, positional, and geometric isomers, salts and salts of isomers
⇒
PubChem: 57501499; ChemSpider: 26286729; Bluelight: Pentedrone; Drugs Forum: Pentedrone; Wikipedia: Pentedrone
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(16)
7542
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(17)
1238
4-Fluoro-N-methylcathinone (4-FMC; Flephedrone; 1-(4-Fluorophenyl)-2-(methylamino)propan-1-one), its optical, positional, and geometric isomers, salts and salts of isomers
UK: MDA Part II Class B Section 1(aa) Flephedrone
⇒
PubChem: 49853406; ChemSpider: 21477355; Drugs Forum: Flephedrone; Erowid: 4-Fluoromethcathinone (4-FMC); Wikipedia: 4-Fluoromethcathinone
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(18)
1233
3-Fluoro-N-methylcathinone (3-FMC; 1-(3-Fluorophenyl)-2-(methylamino)propan-1-one), its optical, positional, and geometric isomers, salts and salts of isomers
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(19)
1258
Naphyrone (Naphthylpyrovalerone; 1-(Naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one), its optical, positional, and geometric isomers, salts and salts of isomers
UK: MDA Part II Class B Section 1(ab) Naphthylpyrovalerone
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 7 Mar 2014, 79 FR 12938 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 28 Jan 2014, 79 FR 4429 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(20)
7546
alpha-Pyrrolidinobutiophenone (α-PBP; 1-Phenyl-2-(pyrrolidin-1-yl)butan-1-one), its optical, positional, and geometric isomers, salts and salts of isomers
Note to hardcore IUPAC junkies: The name given for this substance, like many latter-day cathinones, is a real dog’s breakfast. is not a valid IUPAC name and I suspect never was. I’m guessing it is a recent invention, what linguists call a “back-formation,” patterned after the valid IUPAC name .
derives from the older, now deprecated name for propanoic acid, . It is easy to see how might follow as the name for the four-carbon homologue. In fact is the correct name, derived from , the deprecated name for butanoic acid.
Similarly, is also incorrect. The deprecated name for the five-carbon homologue (pentanoic acid) is , from which derives the correct name . The trivial name pyrovalerone is a contraction of the deprecated (but still valid) name %CE%B1-pyrrolidino-p-methylvalerophenone.
I am indebted to coder extraordinaire Daniel Lowe and his Open Parser for Systematic IUPAC nomenclature (OPSIN), which makes exploring IUPAC nomenclature if not fun, entertaining at least.
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 30 Jan 2015, 80 FR 5042 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 19 Dec 2014, 79 FR 75767 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(21)
7031
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), its optical, positional and geometric isomers, salts and salts of isomers
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 30 Jan 2015, 80 FR 5042 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 19 Dec 2014, 79 FR 75767 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(22)
7023
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA), its optical, positional and geometric isomers, salts and salts of isomers
CA: CDSA Schedule II Section 2 Subsection 8 N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide
methanone](data:image/png;base64,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 "Click for a 3D rendering of [1-(5-Fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone")
Effective 20 Mar 2015, 80 FR 14842 renumbered:
Effective 30 Jan 2015, 80 FR 5042 added, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
On 19 Dec 2014, 79 FR 75767 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(23)
7024
Effective 17 Jul 2015, 80 FR 42381 added:
On 21 May 2015, 80 FR 29227 proposed to add:
(24)
9821
N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (Acetyl fentanyl), its optical, positional, and geometric isomers, salts and salts of isomers
On 16 Sep 2015, 80 FR 55565 proposed to add, for two years’ duration, via the emergency scheduling provision of 21 USC 811(h):
(25)
7032
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMIINACA), its optical, positional, and geometric isomers, salts and salts of isomers
Schedule II [21 CFR 1308.12]
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Source: DEA Office of Diversion Control: Section 1308: Schedules of Controlled Substances
(b)
Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
(1)
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone, and their respective salts, but including the following:
Effective 23 Jan 2015, 80 FR 3468 replacement for:
On 29 Oct 2014, 79 FR 64349 proposed replacement for:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following:
Effective 14 Jul 1992, 57 FR 31126 replacement for:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following:
Effective 4 Nov 1985, 50 FR 45815 replacement for:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, dextrorphan, nalbuphine, naloxone, and naltrexone, and their respective salts, but including the following:
Effective 1 Oct 1976, 41 FR 43401 replacement for:
Opium and opiate, and any salt, compound, derivative, or preparation of opium and opiate, excluding naloxone, naltrexone, and apomorphine, and their respective salts, but including the following:
Effective 28 Jun 1976, 41 FR 26568 replacement for:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding naloxone and its salts, and excluding naltrexone and its salts, but including the following:
Effective 6 Mar 1975, 40 FR 10455 replacement for:
On 9 Dec 1974, 39 FR 42918 proposed replacement for:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding naloxone and its salts, but including the following:
Effective 24 Dec 1974, 39 FR 44392 replacement for:
On 10 Jul 1974, 39 FR 25327 proposed replacement for:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding naloxone hydrochloride, but including the following:
Effective 29 Sep 1971, 36 FR 19116 replacement for:
On 19 Aug 1971, 36 FR 16119 proposed replacement for:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate.
Effective 24 Sep 2007, 72 FR 54208 resequenced items (i) through (xviii) below
Effective 28 Jun 1976, 41 FR 26568 revoked (and renumbered subsequent entries):
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
9030
Apomorphine
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(i)
9050
Effective 17 Nov 2000, 65 FR 69442 added:
(ii)
9334
Dihydroetorphine
UK: MDA Part I Class A Section 1(a) Dihydroetorphine
UN: Narcotics Part 1 Section 1 Dihydroetorphine
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(iii)
9190
Ethylmorphine
CA: CDSA Schedule I Section 1 Subsection 13 Ethylmorphine
UK: MDA Part II Class B Section 1(a) Ethylmorphine
UN: Narcotics Part 1 Section 2 Ethylmorphine and Part 2 Section 1 Ethylmorphine
See also CSA Schedule III Section e Subsection 1 Item iv Ethylmorphine and Schedule V Section c Subsection 3 Ethylmorphine
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(v)
9640
Granulated opium
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(vi)
9193
Hydrocodone
CA: CDSA Schedule I Section 1 Subsection 15 Hydrocodone
UK: MDA Part I Class A Section 1(a) Hydrocodone
UN: Narcotics Part 1 Section 1 Hydrocodone
⇒
PubChem: 5284569; ChemSpider: 4447623; Drugs Forum: Hydrocodone; Erowid: Hydrocodone; Wikipedia: Hydrocodone
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(vii)
9150
Hydromorphone
CA: CDSA Schedule I Section 1 Subsection 17 Hydromorphone
UK: MDA Part I Class A Section 1(a) Hydromorphone
UN: Narcotics Part 1 Section 1 Hydromorphone
⇒
PubChem: 5284570; ChemSpider: 4447624; Drugs Forum: Hydromorphone; Erowid: Hydromorphone; Wikipedia: Hydromorphone
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(ix)
9300
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(x)
9610
Opium extracts
(xi)
9620
Opium fluid
Effective 31 Dec 1969, replacement for:
On 19 Aug 1971, 36 FR 16119 proposed to add:
Opium fluid extracts
Effective 29 Sep 1971, 36 FR 19116 added:
Effective 10 Dec 2007, 72 FR 69618 changed the controlled substance code number of Oripavine to 9330 from 9335
Effective 24 Sep 2007, 72 FR 54208 added:
(xii)
9330
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(xiv)
9652
Oxymorphone
CA: CDSA Schedule I Section 1 Subsection 29 Oxymorphone
UK: MDA Part I Class A Section 1(a) Oxymorphone
UN: Narcotics Part 1 Section 1 Oxymorphone
⇒
PubChem: 5284604; ChemSpider: 4447650; Bluelight: Oxymorphone; Drugs Forum: Oxymorphone; Erowid: Oxymorphone; Wikipedia: OxymorphoneEffective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(xv)
9639
Powdered opium
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(xvi)
9600
Raw opium
See also CSA Schedule III Section e Subsection 1 Item i Opium, Item v Opium and Schedule V Section c Subsection 5 Opium
⇒
PubChem: 167253 202889 202890 17397953 17397584 3842991 202886 202888 413265 3730541; Drugs Forum: Opium; Wikipedia: Opium
Effective 29 Sep 1971, 36 FR 19116 added:
On 19 Aug 1971, 36 FR 16119 proposed to add:
(xviii)
9630
Tincture of opium
(3)
Opium poppy and Poppy straw
Cocaine
Ecgonine
(4)
Coca leaves (9040) and any salt, compound, derivative or preparation of coca leaves (including Cocaine (9041) and Ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include:
Effective 11 Sep 2015, 80 FR 54715 replacement for:
On 3 Jun 2015, 80 FR 31521 proposed replacement for:
Coca leaves (9040) and any salt, compound, derivative or preparation of coca leaves (including Cocaine (9041) and Ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, whhch[sic] extractions do not contain cocaine or ecgonine.
CA: CDSA Schedule I Section 2 Subsection 1 Coca leaves
UK: MDA Part I Class A Section 1(a) Coca leaf
UN: Narcotics Part 1 Section 1 Coca leaf
Effective 11 Sep 2015, 80 FR 54715 added:
On 3 Jun 2015, 80 FR 31521 proposed to add:
(i)
Decocainized Coca leaves or extraction of Coca leaves, which extractions do not contain Cocaine or Ecgonine; or
![3D rendering of [123I]Ioflupane](data:image/png;base64,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 "Click for a 3D rendering of [123I]Ioflupane")
Effective 11 Sep 2015, 80 FR 54715 added:
On 3 Jun 2015, 80 FR 31521 proposed to add:
(ii)
[123I]Ioflupane.
Effective 14 Feb 1975, 40 FR 6779 added:
On 20 Dec 1974, 39 FR 44033 proposed to add:
(5)
9670
Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy).
UK: MDA Part I Class A Section 1(a) Concentrate of poppy-straw
UN: Narcotics Part 1 Section 1 Concentrate of poppy straw
(c)
Opiates. Unless specifically excepted or unless in another schedule any of the following opiates, including its isomers, esters, ethers, salts and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:
Effective 23 Jan 1987, 52 FR 2516 added (and renumbered subsequent entries):
(1)
9737
Alfentanil
CA: CDSA Schedule I Section 16 Subsection 2 Alfentanil
UK: MDA Part I Class A Section 1(a) Alfentanil
UN: Narcotics Part 1 Section 1 Alfentanil
(2)
9010
Alphaprodine
CA: CDSA Schedule I Section 3 Subsection 3 Alphaprodine
UK: MDA Part I Class A Section 1(a) Alphaprodine
UN: Narcotics Part 1 Section 1 Alphaprodine
(3)
9020
Anileridine
CA: CDSA Schedule I Section 3 Subsection 4 Anileridine
UK: MDA Part I Class A Section 1(a) Anileridine
UN: Narcotics Part 1 Section 1 Anileridine
(4)
9800
Bezitramide
CA: CDSA Schedule I Section 13 Subsection 3 Bezitramide
UK: MDA Part I Class A Section 1(a) Bezitramide
UN: Narcotics Part 1 Section 1 Bezitramide
Effective 22 Sep 1980, 45 FR 48881 added (and renumbered subsequent entries):
(5)
9273
Bulk Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane) (non-dosage forms)
CA: CDSA Schedule I Section 7 Subsection 3 Dextropropoxyphene
UK: MDA Part III Class C Section 1(a) Dextropropoxyphene
UN: Narcotics Part 1 Section 2 Dextropropoxyphene and Part 2 Section 3 Dextropropoxyphene
See also CSA Schedule IV Section b Subsection 2 Dextropropoxyphene
Effective 28 Oct 1988, 53 FR 43684 added (and renumbered subsequent entries):
(6)
9743
Carfentanil
CA: CDSA Schedule I Section 16 Subsection 3 Carfentanil
UK: MDA Part I Class A Section 1(a) Carfentanil
(7)
9120
Dihydrocodeine
CA: CDSA Schedule I Section 1 Subsection 11 Dihydrocodeine
UK: MDA Part II Class B Section 1(a) Dihydrocodeine
UN: Narcotics Part 1 Section 2 Dihydrocodeine and Part 2 Section 1 Dihydrocodeine
See also CSA Schedule III Section e Subsection 1 Item iii Dihydrocodeine and Schedule V Section c Subsection 2 Dihydrocodeine
(8)
9170
Diphenoxylate
CA: CDSA Schedule I Section 3 Subsection 8 Diphenoxylate
UK: MDA Part I Class A Section 1(a) Diphenoxylate
UN: Narcotics Part 1 Section 1 Diphenoxylate and Part 2 Section 6 Diphenoxylate
See also CSA Schedule V Section c Subsection 4 Diphenoxylate
(10)
9226
Isomethadone
CA: CDSA Schedule I Section 5 Subsection 3 Isomethadone
UK: MDA Part I Class A Section 1(a) Isomethadone
UN: Narcotics Part 1 Section 1 Isomethadone
Effective 18 Aug 1993, 58 FR 43795 added (and renumbered subsequent entries):
(11)
9648
Levo-alphacetylmethadol (Levo-alpha-acetylmethadol; Levomethadyl acetate; LAAM)
(12)
9210
Levomethorphan
CA: CDSA Schedule I Section 10 Subsection 3 Levomethorphan
UK: MDA Part I Class A Section 1(a) Levomethorphan
UN: Narcotics Part 1 Section 1 Levomethorphan
⇒
PubChem: 5362449; ChemSpider: 4642423; Bluelight: Levomethorphan; Drugs Forum: Levomethorphan; Wikipedia: Levomethorphan
(13)
9220
Levorphanol
CA: CDSA Schedule I Section 10 Subsection 4 Levorphanol
UK: MDA Part I Class A Section 1(a) Levorphanol
UN: Narcotics Part 1 Section 1 Levorphanol
⇒
PubChem: 5359272; ChemSpider: 16736212; Bluelight: Levorphanol ; Drugs Forum: Levorphanol ; Erowid: Levorphanol Synthesis; Wikipedia: Levorphanol
(14)
9240
Metazocine
CA: CDSA Schedule I Section 11 Subsection 2 Metazocine
UK: MDA Part I Class A Section 1(a) Metazocine and Part II Class B Section 1(a) Metazocine
UN: Narcotics Part 1 Section 1 Metazocine and Psychotropics Schedule III Metazocine
(16)
9254
Methadone-intermediate (4-Cyano-2-dimethylamino-4,4-diphenyl butane)
CA: CDSA Schedule I Section 5 Subsection 1 Dimethylaminodiphenylbutanonitrile
UK: MDA Part I Class A Section 1(a) 4-Cyano-2-dimethylamino-4,4-diphenylbutane
UN: Narcotics Part 1 Section 1 Methadone intermediate
(17)
9802
Moramide-intermediate (2-Methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid)
CA: CDSA Schedule I Section 9 Subsection 2 Diphenylmorpholinoisovaleric acid
UK: MDA Part I Class A Section 1(a) 2-Methyl-3-morpholino-1,1-diphenylpropanecarboxylic acid
UN: Narcotics Part 1 Section 1 Moramide intermediate
(19)
9232
Pethidine-intermediate-A (4-Cyano-1-methyl-4-phenylpiperidine)
CA: CDSA Schedule I Section 3 Subsection 14 Methylphenylisonipecotonitrile
UK: MDA Part I Class A Section 1(a) 4-Cyano-1-methyl-4-phenylpiperidine
UN: Narcotics Part 1 Section 1 Pethidine intermediate A
(20)
9233
Pethidine-intermediate-B (Ethyl-4-phenylpiperidine-4-carboxylate)
CA: CDSA Schedule I Section 3 Subsection 16 Norpethidine
UK: MDA Part I Class A Section 1(a) 4-Phenylpiperidine-4-carboxylic acid ethyl ester
UN: Narcotics Part 1 Section 1 Pethidine intermediate B
(21)
9234
Pethidine-intermediate-C (1-Methyl-4-phenylpiperidine-4-carboxylic acid)
CA: CDSA Schedule I Section 3 Subsection 22 Pethidine intermediate C
UK: MDA Part I Class A Section 1(a) 1-Methyl-4-phenylpiperidine-4-carboxylic acid
UN: Narcotics Part 1 Section 1 Pethidine intermediate C
(22)
9715
Phenazocine
CA: CDSA Schedule I Section 11 Subsection 1 Phenazocine
UK: MDA Part I Class A Section 1(a) Phenazocine
UN: Narcotics Part 1 Section 1 Phenazocine
(23)
9730
Piminodine
CA: CDSA Schedule I Section 3 Subsection 19 Piminodine
UK: MDA Part I Class A Section 1(a) Piminodine
UN: Narcotics Part 1 Section 1 Piminodine
(24)
9732
Racemethorphan
CA: CDSA Schedule I Section 10 Subsection 8 Racemethorphan
UK: MDA Part I Class A Section 1(a) Racemethorphan
UN: Narcotics Part 1 Section 1 Racemethorphan
(25)
9733
Racemorphan
CA: CDSA Schedule I Section 10 Subsection 9 Racemorphan
UK: MDA Part I Class A Section 1(a) Racemorphan
UN: Narcotics Part 1 Section 1 Racemorphan
Effective 5 Nov 1996, 61 FR 56893 added:
On 16 Sep 1996, 61 FR 48655 proposed to add:
(26)
9739
Remifentanil
CA: CDSA Schedule I Section 16 Subsection 11.1 Remifentanil
UK: MDA Part I Class A Section 1(a) Remifentanil
UN: Narcotics Part 1 Section 1 Remifentanil
Effective 25 May 1984, 49 FR 22074 added:
(27)
9740
Sufentanil
CA: CDSA Schedule I Section 16 Subsection 12 Sufentanil
UK: MDA Part I Class A Section 1(a) Sufentanil
UN: Narcotics Part 1 Section 1 Sufentanil
⇒
PubChem: 41693; ChemSpider: 38043; Bluelight: Sufentanil; Erowid: Sufentanil total synthesis; Wikipedia: Sufentanil
Effective 22 Jun 2009, 74 FR 23790 added:
On 17 Feb 2009, 74 FR 7386 proposed to add:
(28)
9780
Tapentadol
CA: CDSA Schedule I Section 22 Tapentadol
UK: MDA Part I Class A Section 1(a) Tapentadol
⇒
PubChem: 9838022; ChemSpider: 8013742; Bluelight: Tapentadol; Drugs Forum: Tapentadol; Erowid: Tapentadol; Wikipedia: Tapentadol(d)
Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:
Effective 7 Jul 1971, 36 FR 12734 replacement for:
On 26 May 1971, 36 FR 9563 proposed replacement for:
Unless specifically excepted or unless listed in another schedule, any injectable liquid which contains any quantity of methamphetamine, including its salts, isomers, and salts of its isomers.
Effective 7 Jul 1971, 36 FR 12734 added:
On 26 May 1971, 36 FR 9563 proposed to add:
(1)
1100
Amphetamine, its salts, optical isomers, and salts of its optical isomers
CA: CDSA Schedule I Section 19 Subsection 1 Amphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 1 Amphetamine
UK: MDA Part II Class B Section 1(a) Amphetamine
UN: Psychotropics Schedule II Amfetamine (Amphetamine)
⇒
PubChem: 3007; ChemSpider: 13852819; Bluelight: Amphetamine; Drugs Forum: Amphetamine; Erowid: Amphetamine; Wikipedia: Amphetamine
Effective 7 Jul 1971, 36 FR 12734 added:
On 26 May 1971, 36 FR 9563 proposed to add:
(2)
1105
Methamphetamine, its salts, isomers, and salts of its isomers
CA: CDSA Schedule I Section 18 Methamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 23 Methamphetamine
UK: MDA Part I Class A Section 1(a) Methylamphetamine
UN: Psychotropics Schedule II Metamfetamine racemate (Methamphetamine racemate)
⇒
PubChem: 1206; ChemSpider: 1169; Bluelight: Methamphetamine; Drugs Forum: Methamphetamine; Erowid: Meth; Wikipedia: Methamphetamine
Effective 28 Oct 1971, 36 FR 20686 added:
On 17 Sep 1971, 36 FR 18582 proposed to add:
(3)
1631
Phenmetrazine and its salts
CA: CDSA Schedule IV Section 6 Phenmetrazine
UK: MDA Part II Class B Section 1(a) Phenmetrazine
UN: Psychotropics Schedule II Phenmetrazine
Effective 28 Oct 1971, 36 FR 20686 added:
On 17 Sep 1971, 36 FR 18582 proposed to add:
(4)
1724
Methylphenidate
CA: CDSA Schedule III Section 2 Methylphenidate
UK: MDA Part II Class B Section 1(a) Methylphenidate
UN: Psychotropics Schedule II Methylphenidate
⇒
PubChem: 4158; ChemSpider: 4015; Bluelight: Methylphenidate; Drugs Forum: Methylphenidate; Erowid: Methylphenidate; Wikipedia: Methylphenidate
Effective 4 Jun 2007, 72 FR 24532 added:
On 22 Feb 2007, 72 FR 7945 proposed to add:
(5)
1205
Lisdexamfetamine, its salts, isomers, and salts of isomers
UK: MDA Part II Class B Section 1(a) Lisdexamfetamine
Effective 4 Oct 1973, 38 FR 27516 added:
(e)
Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
Effective 27 Aug 1984, 49 FR 33870 revoked (and renumbered subsequent entries):
Effective 4 Oct 1973, 38 FR 27516 added:
On 11 Apr 1973, 38 FR 9170 proposed to add:
Methaqualone
US: Currently at CSA Schedule I Section e Subsection 3 Methaqualone
Effective 13 Nov 1973, 38 FR 31310 added:
(1)
2125
Amobarbital
CA: CDSA Schedule IV Section 1 Subsection 3 Amobarbital
UN: Psychotropics Schedule III Amobarbital
See also CSA Schedule III Section c Subsection 1 Item i Amobarbital and Subsection 2 Item i Amobarbital
Effective 21 Mar 1991, 56 FR 11930 added (and renumbered subsequent entries):
(2)
2550
Glutethimide
CA: CDSA Schedule IV Section 11 Glutethimide
UK: MDA Part II Class B Section 1(a) Glutethimide
UN: Psychotropics Schedule III Glutethimide
Effective 13 Nov 1973, 38 FR 31310 added:
(3)
2270
Pentobarbital
CA: CDSA Schedule IV Section 1 Subsection 20 Pentobarbital
UN: Psychotropics Schedule III Pentobarbital
See also CSA Schedule III Section c Subsection 1 Item iii Pentobarbital and Subsection 2 Item iii Pentobarbital
⇒
PubChem: 4737; ChemSpider: 4575; Bluelight: Pentobarbital; Drugs Forum: Pentobarbital; Erowid: Barbiturates; Wikipedia: Pentobarbital
Effective 24 Feb 1978, 43 FR 3359 added (and renumbered subsequent entries):
(4)
7471
Phencyclidine
CA: CDSA Schedule I Section 14 Phencyclidine
UK: MDA Part I Class A Section 1(a) Phencyclidine
UN: Psychotropics Schedule II Phencyclidine (PCP)
⇒
PubChem: 6468; ChemSpider: 6224; Bluelight: PCP; Drugs Forum: Phencyclidine; Erowid: PCP; Wikipedia: PhencyclidineEffective 11 Feb 1980, 44 FR 71822 revoked:
Effective 16 Jun 1978, 43 FR 21324 added:
(a)
7460
1-Phenylcyclohexylamine
US: Currently at CSA Schedule II Section g Subsection 2 Item i 1-Phenylcyclohexylamine
Effective 11 Feb 1980, 44 FR 71822 revoked:
Effective 16 Jun 1978, 43 FR 21324 added:
(b)
8603
1-Piperidinocyclohexanecarbonitrile (PCC)
US: Currently at CSA Schedule II Section g Subsection 2 Item ii 1-Piperidinocyclohexanecarbonitrile
Effective 21 Sep 1973, 38 FR 26447 added:
(5)
2315
Secobarbital
CA: CDSA Schedule IV Section 1 Subsection 24 Secobarbital
UN: Psychotropics Schedule II Secobarbital
See also CSA Schedule III Section c Subsection 1 Item ii Secobarbital and Subsection 2 Item ii Secobarbital
⇒
PubChem: 5193; ChemSpider: 5005; Bluelight: Secobarbital bioavailability; Drugs Forum: Secobarbital; Erowid: Barbiturates; Wikipedia: SecobarbitalEffective 2 Jul 1999, 64 FR 35928 revoked (and renumbered subsequent entries):
On 5 Nov 1998, 63 FR 59751 proposed to revoke (and to renumber subsequent entries:)
7369
Dronabinol ((6aR-trans)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; (-)-Delta-9-(trans)-tetrahydrocannabinol)
US: Currently at CSA Schedule III Section g Subsection 1 Dronabinol
Effective 11 Feb 1980, 44 FR 71822 added:
(g)
Immediate precursors. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:
Effective 11 Feb 1980, 44 FR 71822 added:
(1)
Immediate precursor to Amphetamine and Methamphetamine:
Effective 11 Feb 1980, 44 FR 71822 added:
(i)
8501
Phenylacetone (Phenyl-2-propanone; P2P; Benzyl methyl ketone; Methyl benzyl ketone)
CA: CDSA Schedule VI Part 1 Subsection 11 1-Phenyl-2-propanone
EU: Drug precursors Annex I Category 1 1-Phenyl-2-propanone
UK: MDA Drug precursors Annex I Category 1 1-Phenyl-2-propanone
UN: Precursors Table I 1-Phenyl-2-propanone
Effective 29 Jun 2010, 75 FR 37295 added:
On 9 Apr 2008, 73 FR 19175 proposed to add:
(3)
Immediate precursor to Fentanyl:
Effective 29 Jun 2010, 75 FR 37295 added:
On 9 Apr 2008, 73 FR 19175 proposed to add:
(ii)
[Reserved]
Schedule III [21 CFR 1308.13]
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Source: DEA Office of Diversion Control: Section 1308: Schedules of Controlled Substances
(b)
Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous sxstem[sic], including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
Effective 7 Jul 1971, 36 FR 12734 revoked (and renumbered subsequent entries):
On 26 May 1971, 36 FR 9563 proposed to revoke (and to renumber subsequent entries:)
Amphetamine, its salts, optical isomers, and salts of its optical isomers.
US: Currently at CSA Schedule II Section d Subsection 1 Amphetamine
Effective 28 Oct 1971, 36 FR 20686 revoked (and renumbered subsequent entries):
Phenmetrazine and its salts.
US: Currently at CSA Schedule II Section d Subsection 3 Phenmetrazine
Effective 7 Jul 1971, 36 FR 12734 revoked (and renumbered subsequent entries):
On 26 May 1971, 36 FR 9563 proposed to revoke (and to renumber subsequent entries:)
Any substance (except an injectable liquid) which contains any quantity of Methamphetamine, including its salts, isomers, and salts of isomers.
US: Currently at CSA Schedule II Section d Subsection 2 Methamphetamine
Effective 28 Oct 1971, 36 FR 20686 revoked (and renumbered subsequent entries):
Methylphenidate
US: Currently at CSA Schedule II Section d Subsection 4 Methylphenidate
(1)
1405
Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Sec. 1308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances
Effective 31 Dec 1969, replacement for:
Effective 15 Jun 1973, 38 FR 15719 replacement for:
Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under §308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances.
On 26 May 1971, 36 FR 9563 proposed to add:
Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances which are currently listed as exected compounds under 21 CFR 308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances.
Effective 7 Jul 1971, 36 FR 12734 added:
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12119 proposed to add:
(2)
1228
Benzphetamine
CA: CDSA Schedule I Section 19 Subsection 17 Benzphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 18 Benzphetamine
UK: MDA Part III Class C Section 1(a) Benzphetamine
UN: Psychotropics Schedule IV Benzfetamine (Benzphetamine)
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12120 proposed to add:
(3)
1645
Chlorphentermine
CA: CDSA Schedule IV Section 3 Chlorphentermine
UK: MDA Part III Class C Section 1(a) Chlorphentermine
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12121 proposed to add:
(4)
1647
Clortermine
On 9 May 1973, 38 FR 12230 proposed to add:
Diethylpropion
US: Currently at CSA Schedule IV Section f Subsection 2 Diethylpropion
Effective 27 Nov 1981, 46 FR 52333 revoked (and renumbered subsequent entries):
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12124 proposed to add:
Mazindol
US: Currently at CSA Schedule IV Section f Subsection 5 Mazindol
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12126 proposed to add:
(5)
1615
Phendimetrazine
CA: CDSA Schedule IV Section 5 Phendimetrazine
UK: MDA Part III Class C Section 1(a) Phendimetrazine
UN: Psychotropics Schedule IV Phendimetrazine
On 9 May 1973, 38 FR 12127 proposed to add:
Phentermine
US: Currently at CSA Schedule IV Section f Subsection 9 Phentermine
Effective 13 Nov 1973, 38 FR 31310 renumbered:
(c)
Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:
(1)
Any compound, mixture or preparation containing:
Effective 31 Dec 1969, replacement for:
Effective 13 Nov 1973, 38 FR 31310 added (and renumbered subsequent entries):
Any compound, mixture or preparation containing Amobarbital, Secobarbital, Pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.
(i)
2126
Amobarbital
CA: CDSA Schedule IV Section 1 Subsection 3 Amobarbital
UN: Psychotropics Schedule III Amobarbital
See also CSA Schedule II Section e Subsection 1 Amobarbital and Schedule III Section c Subsection 2 Item i Amobarbital
(ii)
2316
Secobarbital
CA: CDSA Schedule IV Section 1 Subsection 24 Secobarbital
UN: Psychotropics Schedule II Secobarbital
See also CSA Schedule II Section e Subsection 5 Secobarbital and Schedule III Section c Subsection 2 Item ii Secobarbital
⇒
PubChem: 5193; ChemSpider: 5005; Bluelight: Secobarbital bioavailability; Drugs Forum: Secobarbital; Erowid: Barbiturates; Wikipedia: Secobarbital
(iii)
2271
Pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.
CA: CDSA Schedule IV Section 1 Subsection 20 Pentobarbital
UN: Psychotropics Schedule III Pentobarbital
See also CSA Schedule II Section e Subsection 3 Pentobarbital and Schedule III Section c Subsection 2 Item iii Pentobarbital
⇒
PubChem: 4737; ChemSpider: 4575; Bluelight: Pentobarbital; Drugs Forum: Pentobarbital; Erowid: Barbiturates; Wikipedia: Pentobarbital(2)
Any suppository dosage form containing:
Effective 31 Dec 1969, replacement for:
Effective 13 Nov 1973, 38 FR 31310 added (and renumbered subsequent entries):
Any suppository dosage form containing containing Amobarbital, Secobarbital, Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.
(i)
2126
Amobarbital
CA: CDSA Schedule IV Section 1 Subsection 3 Amobarbital
UN: Psychotropics Schedule III Amobarbital
See also CSA Schedule II Section e Subsection 1 Amobarbital and Schedule III Section c Subsection 1 Item i Amobarbital
(ii)
2316
Secobarbital
CA: CDSA Schedule IV Section 1 Subsection 24 Secobarbital
UN: Psychotropics Schedule II Secobarbital
See also CSA Schedule II Section e Subsection 5 Secobarbital and Schedule III Section c Subsection 1 Item ii Secobarbital
⇒
PubChem: 5193; ChemSpider: 5005; Bluelight: Secobarbital bioavailability; Drugs Forum: Secobarbital; Erowid: Barbiturates; Wikipedia: Secobarbital
(iii)
2271
Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.
CA: CDSA Schedule IV Section 1 Subsection 20 Pentobarbital
UN: Psychotropics Schedule III Pentobarbital
See also CSA Schedule II Section e Subsection 3 Pentobarbital and Schedule III Section c Subsection 1 Item iii Pentobarbital
⇒
PubChem: 4737; ChemSpider: 4575; Bluelight: Pentobarbital; Drugs Forum: Pentobarbital; Erowid: Barbiturates; Wikipedia: Pentobarbital
(3)
2100
Any substance which contains any quantity of a derivative of Barbituric acid or any salt thereof
Effective 13 Nov 1973, 38 FR 31310 replacement for:
Any substance which contains any quantity of a derivative of Barbituric acid, or any salt of a derivative of Barbituric acid.
CA: CDSA Schedule IV Section 1 Subsection 6 Barbituric acid
Effective 28 Sep 2006, 71 FR 51115 added (and renumbered subsequent entries):
On 29 Aug 2005, 70 FR 50996 extended the comment period of the earlier proposal to 28 Sept 2005 from 29 Aug 2005
On 29 Jul 2005, 70 FR 43809 proposed to add (and to renumber subsequent entries):
(5)
2020
Embutramide
Effective 21 Mar 1991, 56 FR 11930 revoked (and renumbered subsequent entries):
2550
Glutethimide
US: Currently at CSA Schedule II Section e Subsection 2 Glutethimide
Effective 3 Apr 2000, 65 FR 17440 corrected an error in amendatory instruction 3 of 68 FR 13235
Effective 13 Mar 2000, 65 FR 13235 added (and renumbered subsequent entries):
(6)
2012
Any drug product containing Gamma-hydroxybutyric acid (GHB; Gamma-hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic acid; Sodium oxybate; Sodium oxybutyrate), including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act
CA: CDSA Schedule I Section 21 4-Hydroxybutanoic acid
CA: [revoked] CDSA Schedule III Section 26 4-Hydroxybutanoic acid
UK: MDA Part III Class C Section 1(a) 4-Hydroxy-n-butyric acid
UN: Psychotropics Schedule II GHB
UN: [revoked] Psychotropics Schedule IV GHB
See also CSA Schedule I Section e Subsection 1 Gamma-hydroxybutyric acid
⇒
PubChem: 10413; ChemSpider: 9984; Drugs Forum: GHB; Erowid: GHB; Wikipedia: gamma-Hydroxybutyric acid
Effective 12 Aug 1999, 64 FR 37673 added:
On 9 Apr 1999, 64 FR 17299 proposed to add:
(7)
7285
Ketamine ((±)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone), its salts, isomers, and salts of isomers
(8)
7300
Lysergic acid
CA: CDSA Schedule VI Part 1 Subsection 8 Lysergic acid
EU: Drug precursors Annex I Category 1 Lysergic acid
UK: MDA Drug precursors Annex I Category 1 Lysergic acid
UN: Precursors Table I Lysergic acid
(10)
2575
Methyprylon
CA: CDSA Schedule IV Section 17 Methyprylon
UK: MDA Part III Class C Section 1(a) Methyprylone
UN: Psychotropics Schedule IV Methyprylon
Effective 14 Mar 1977, 42 FR 8636 revoked (and renumbered subsequent entries):
7471
Phencyclidine
US: Currently at CSA Schedule II Section e Subsection 4 Phencyclidine
Effective 2 Dec 2013, 78 FR 72013 added (and renumbered subsequent entries):
On 22 Oct 2013, 78 FR 62500 proposed to add (and to renumber subsequent entries):
(11)
2261
Perampanel, and its salts, isomers, and salts of isomers
Tiletamine
Zolazepam
Effective 20 Feb 1987, 52 FR 2221 added:
(15)
7295
Tiletamine (2-(Ethylamino)-2-(2-thienyl)cyclohexanone) and Zolazepam (4-(2-Fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo[3,4-e][1,4]diazepin-7(1H)-one; Flupyrazapon) or any salt thereof
Some trade or other names for a Tiletamine-Zolazepam combination product: Telazol
⇒
PubChem: 26533; ChemSpider: 24714; Bluelight: Tiletamine; Drugs Forum: Tiletamine; Erowid: Tiletamine; Wikipedia: Tiletamine
(e)
Narcotic Drugs. Unless specifically excepted or unless listed in another schedule:
Effective 7 Oct 2002, 67 FR 62354 replacement for:
On 21 Mar 2002, 67 FR 13114 proposed replacement for:
Narcotic Drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
Effective 7 Oct 2002, 67 FR 62354 added (and renumbered subsequent entries):
On 21 Mar 2002, 67 FR 13114 proposed to add (and to renumber subsequent entries):
(1)
Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(i)
9803
Not more than 1.8 grams of Codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of Opium
See also CSA Schedule II Section b Subsection 1 Item i Codeine, Schedule III Section e Subsection 1 Item ii Codeine and Schedule V Section c Subsection 1 Codeine
See also CSA Schedule II Section b Subsection 1 Item xvi Raw opium, Schedule III Section e Subsection 1 Item v Opium and Schedule V Section c Subsection 5 Opium
⇒
PubChem: 167253 202889 202890 17397953 17397584 3842991 202886 202888 413265 3730541; Drugs Forum: Opium; Wikipedia: Opium
(ii)
9804
Not more than 1.8 grams of Codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts
Effective 6 Oct 2014, 79 FR 49661 revoked (and renumbered subsequent entries):
On 27 Feb 2014, 79 FR 11037 proposed to revoke (and to renumber subsequent entries:)
9805
Not more than 300 milligrams of Dihydrocodeinone (Hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of Opium
CA: CDSA Schedule I Section 1 Subsection 15 Hydrocodone
UK: MDA Part I Class A Section 1(a) Hydrocodone
UN: Narcotics Part 1 Section 1 Hydrocodone
⇒
PubChem: 5284569; ChemSpider: 4447623; Drugs Forum: Hydrocodone; Erowid: Hydrocodone; Wikipedia: Hydrocodone⇒
PubChem: 167253 202889 202890 17397953 17397584 3842991 202886 202888 413265 3730541; Drugs Forum: Opium; Wikipedia: Opium
Effective 6 Oct 2014, 79 FR 49661 revoked (and renumbered subsequent entries):
On 27 Feb 2014, 79 FR 11037 proposed to revoke (and to renumber subsequent entries:)
9806
Not more than 300 milligrams of Dihydrocodeinone (Hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts
CA: CDSA Schedule I Section 1 Subsection 15 Hydrocodone
UK: MDA Part I Class A Section 1(a) Hydrocodone
UN: Narcotics Part 1 Section 1 Hydrocodone
⇒
PubChem: 5284569; ChemSpider: 4447623; Drugs Forum: Hydrocodone; Erowid: Hydrocodone; Wikipedia: Hydrocodone
(iii)
9807
Not more than 1.8 grams of Dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts
CA: CDSA Schedule I Section 1 Subsection 11 Dihydrocodeine
UK: MDA Part II Class B Section 1(a) Dihydrocodeine
UN: Narcotics Part 1 Section 2 Dihydrocodeine and Part 2 Section 1 Dihydrocodeine
See also CSA Schedule II Section c Subsection 7 Dihydrocodeine and Schedule V Section c Subsection 2 Dihydrocodeine
(iv)
9808
Not more than 300 milligrams of Ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts
CA: CDSA Schedule I Section 1 Subsection 13 Ethylmorphine
UK: MDA Part II Class B Section 1(a) Ethylmorphine
UN: Narcotics Part 1 Section 2 Ethylmorphine and Part 2 Section 1 Ethylmorphine
See also CSA Schedule II Section b Subsection 1 Item iii Ethylmorphine and Schedule V Section c Subsection 3 Ethylmorphine
(v)
9809
Not more than 500 milligrams of Opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts
See also CSA Schedule II Section b Subsection 1 Item xvi Raw opium, Schedule III Section e Subsection 1 Item i Opium and Schedule V Section c Subsection 5 Opium
⇒
PubChem: 167253 202889 202890 17397953 17397584 3842991 202886 202888 413265 3730541; Drugs Forum: Opium; Wikipedia: Opium
(vi)
9810
Not more than 50 milligrams of Morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts
Effective 7 Oct 2002, 67 FR 62354 added:
On 21 Mar 2002, 67 FR 13114 proposed to add:
(2)
Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts as set forth below:
Effective 7 Oct 2002, 67 FR 62354 added:
On 21 Mar 2002, 67 FR 13114 proposed to add:
(i)
9064
Buprenorphine
CA: CDSA Schedule I Section 10 Subsection 1 Buprenorphine
UK: MDA Part III Class C Section 1(a) Buprenorphine
UN: Psychotropics Schedule III Buprenorphine
⇒
PubChem: 40400 644073; ChemSpider: 559124; Bluelight: Buprenorphine; Drugs Forum: Buprenorphine; Erowid: Buprenorphine; Wikipedia: BuprenorphineEffective 7 Oct 2002, 67 FR 62354 added:
On 21 Mar 2002, 67 FR 13114 proposed to add:
(ii)
(f)
Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation:
Readers wanting to explore the intricacies of steroid nomenclature may find this steroid crib sheet useful.
(1)
4000
Anabolic steroids (see §1300.01 of this chapter)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Anabolic Steroids
From 21 CFR 1300.01 Definitions relating to controlled substances
Anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:
Anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:
Effective 27 Jan 2012, 77 FR 4228 replacement for:
[From 21 CFR 1300.01 Definitions relating to controlled substances]
…(4) The term anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
[From 21 CFR 1308.02 Definitions]
…(b) The term anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins and corticosteroids) that promotes muscle growth, and includes:
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(1)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(2)
3α,17β-Dihydroxy-5α-androstane
UK: MDA Part III Class C Section 1(b) 5α-Androstane-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(3)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(4)
1-Androstenediol (3β,17β-Dihydroxy-5α-androst-1-ene)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(5)
1-Androstenediol (3α,17β-Dihydroxy-5α-androst-1-ene)
UK: MDA Part III Class C Section 1(b) 1-Androstenediol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(6)
4-Androstenediol (3β,17β-Dihydroxyandrost-4-ene)
UK: MDA Part III Class C Section 1(b) Androst-4-ene-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(7)
5-Androstenediol (3β,17β-Dihydroxyandrost-5-ene)
CA: CDSA Schedule IV Section 23 Subsection 3 Androstenediol
UK: MDA Part III Class C Section 1(b) 5-Androstene-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(8)
1-Androstenedione ([5α]-Androst-1-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 1-Androstenedione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(9)
4-Androstenedione (Androst-4-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 4-Androstene-3,17-dione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(10)
5-Androstenedione (Androst-5-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 5-Androstenedione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(11)
Bolasterone (7α,17α-Dimethyl-17β-hydroxyandrost-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 5 Bolasterone
UK: MDA Part III Class C Section 1(b) Bolasterone
(12)
Boldenone (17β-Hydroxyandrost-1,4-diene-3-one)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Boldenone (17β-Hydroxyandrost-1,4,-diene-3-one)
Effective 27 Feb 1991, 56 FR 5753 added:
Boldenone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 4 Jan 2010, 74 FR 63603 added (and renumbered subsequent entries):
On 25 Apr 2008, 73 FR 22294 proposed to add (and to renumber subsequent entries):
(13)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(14)
Calusterone (7β,17α-Dimethyl-17β-hydroxyandrost-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 9 Calusterone
UK: MDA Part III Class C Section 1(b) Calusterone
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Chlorotestosterone (4-Chlortestosterone)
Chlorotestosterone is a synonym for Clostebol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(15)
Clostebol (4-Chloro-17β-hydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Clostebol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(16)
Dehydrochloromethyltestosterone (4-Chloro-17β-hydroxy-17α-methylandrost-1,4-dien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Dehydrochlormethyltestosterone
UK: MDA Part III Class C Section 1(b) 4-Chloromethandienone
⇒
PubChem: 16395944; ChemSpider: 88972; Erowid: Steroids; Wikipedia: 4-Chlorodehydromethyltestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 4 Jan 2010, 74 FR 63603 added (and renumbered subsequent entries):
On 25 Apr 2008, 73 FR 22294 proposed to add (and to renumber subsequent entries):
(17)
Desoxymethyltestosterone (17α-Methyl-5α-androst-2-en-17β-ol; Madol)
UK: MDA Part III Class C Section 1(b) Desoxymethyltestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(18)
Δ1-Dihydrotestosterone (1-Testosterone; 17β-Hydroxy-5α-androst-1-en-3-one)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(19)
4-Dihydrotestosterone (17β-Hydroxyandrostan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Dihydrotestosterone (4-Dihydrotestosterone)
CA: CDSA Schedule IV Section 23 Subsection 2 Androstanolone
UK: MDA Part III Class C Section 1(b) Stanolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(20)
Drostanolone (17β-Hydroxy-2α-methyl-5α-androstan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Drostanolone
CA: CDSA Schedule IV Section 23 Subsection 11 Drostanolone
UK: MDA Part III Class C Section 1(b) Drostanolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(21)
Ethylestrenol (17α-Ethyl-17β-hydroxyestr-4-ene)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Ethylestrenol
CA: CDSA Schedule IV Section 23 Subsection 14 Ethylestrenol
UK: MDA Part III Class C Section 1(b) Ethyloestrenol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(22)
Fluoxymesterone (9-Fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Fluoxymesterone
CA: CDSA Schedule IV Section 23 Subsection 16 Fluoxymesterone
UK: MDA Part III Class C Section 1(b) Fluoxymesterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(23)
Formebolone (2-Formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Formebulone (Formebolone)
CA: CDSA Schedule IV Section 23 Subsection 17 Formebolone
UK: MDA Part III Class C Section 1(b) Formebolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(24)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(25)
13β-Ethyl-17β-hydroxygon-4-en-3-one
Effective 13 Oct 2006, 71 FR 60426 replacement for:
13β-Ethyl-17α-hydroxygon-4-en-3-one
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(26)
4-Hydroxytestosterone (4,17β-Dihydroxyandrost-4-en-3-one)
[With thanks to Jan of Palo Alto for reporting an error in the structural diagram shown previously for this substance.]
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(27)
4-Hydroxy-19-nortestosterone (4,17β-Dihydroxy-estr-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 15 4-Hydroxy-19-nortestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(28)
Mestanolone (17α-Methyl-17β-hydroxy-5α-androstan-3-one)
UK: MDA Part III Class C Section 1(b) Mestanolone
(29)
Mesterolone (1α-Methyl-17β-hydroxy-[5α]-androstan-3-one)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Mesterolone (1αMethyl-17β-hydroxy-[5α]-androstan-3-one)
Effective 27 Feb 1991, 56 FR 5753 added:
Mesterolone
CA: CDSA Schedule IV Section 23 Subsection 21 Mesterolone
UK: MDA Part III Class C Section 1(b) Mesterolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(30)
Methandienone (17α-Methyl-17β-hydroxyandrost-1,4-dien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandienone
CA: CDSA Schedule IV Section 23 Subsection 22 Metandienone
UK: MDA Part III Class C Section 1(b) Methandienone
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandranone
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(31)
Methandriol (17α-Methyl-3β,17β-dihydroxyandrost-5-ene)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandriol
CA: CDSA Schedule IV Section 23 Subsection 24 Methandriol
UK: MDA Part III Class C Section 1(b) Methandriol
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandrostenolone
Methandrostenolone is a synonym for Methandienone
Effective 29 Aug 2012, 77 FR 44456 added (and renumbered subsequent entries):
On 23 Nov 2011, 76 FR 72355 proposed to add (and to renumber subsequent entries):
(32)
Methasterone (2α,17α-Dimethyl-5α-androstan-17β-ol-3-one)
See also CSA Schedule III Section f Subsection 1 Item 73 2α,17α-Dimethyl-17β-hydroxy-5α-androstan-3-one
⇒
PubChem: 237186; ChemSpider: 207079; Bluelight: Superdrol; Erowid: Steroids; Wikipedia: Methasterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(33)
Methenolone (1-Methyl-17β-hydroxy-5α-androst-1-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methenolone
CA: CDSA Schedule IV Section 23 Subsection 23 Metenolone
UK: MDA Part III Class C Section 1(b) Methenolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(34)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(35)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(36)
17α-Methyl-3β,17β-dihydroxyandrost-4-ene
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(37)
17α-Methyl-4-hydroxynandrolone (17α-Methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(38)
Methyldienolone (17α-Methyl-17β-hydroxyestra-4,9(10)-dien-3-one)
(39)
Methyltrienolone (17α-Methyl-17β-hydroxyestra-4,9,11-trien-3-one)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
Methyltrienolone (17α-Methyl-17β-hydroxyestra-4,9-11-trien-3-one)
CA: CDSA Schedule IV Section 23 Subsection 26 Metribolone
UK: MDA Part III Class C Section 1(b) Metribolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(40)
Methyltestosterone (17α-Methyl-17β-hydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methyltestosterone
CA: CDSA Schedule IV Section 23 Subsection 25 Methyltestosterone
UK: MDA Part III Class C Section 1(b) Methyltestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(41)
Mibolerone (7α,17α-Dimethyl-17β-hydroxyestr-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Mibolerone
CA: CDSA Schedule IV Section 23 Subsection 27 Mibolerone
UK: MDA Part III Class C Section 1(b) Mibolerone
(42)
17α-Methyl-Δ1-dihydrotestosterone (17β-Hydroxy-17α-methyl-5α-androst-1-en-3-one; 17α-Methyl-1-testosterone)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
17α-Methyl-Δ1-dihydrotestosterone (17bβ-Hydroxy-17α-methyl-5α-androst-1-en-3-one; 17α-Methyl-1-testosterone)
⇒
PubChem: 7092657; ChemSpider: 5442174; Bluelight: Methyl-1-Testosterone; Drugs Forum: M-1-T; Erowid: Steroids; Wikipedia: Methyl-1-testosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(43)
Nandrolone (17β-Hydroxyestr-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Nandrolone
CA: CDSA Schedule IV Section 23 Subsection 28 Nandrolone
UK: MDA Part III Class C Section 1(b) Nandrolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(44)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(45)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(46)
19-Nor-5-androstenediol (3β,17β-Dihydroxyestr-5-ene)
UK: MDA Part III Class C Section 1(b) 19-Nor-5-androstene-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(47)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 4 Jan 2010, 74 FR 63603 added (and renumbered subsequent entries):
On 25 Apr 2008, 73 FR 22294 proposed to add (and to renumber subsequent entries):
(48)
19-Nor-4,9(10)-androstadienedione (Estra-4,9(10)-diene-3,17-dione)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(49)
19-Nor-4-androstenedione (Estr-4-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 19-Nor-4-androstene-3,17-dione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(50)
19-Nor-5-androstenedione (Estr-5-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 19-Norandrostenedione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(51)
Norbolethone (13β,17α-Diethyl-17β-hydroxygon-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 29 Norboletone
UK: MDA Part III Class C Section 1(b) Norboletone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(52)
Norclostebol (4-Chloro-17β-hydroxyestr-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 30 Norclostebol
UK: MDA Part III Class C Section 1(b) Norclostebol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(53)
Norethandrolone (17α-Ethyl-17β-hydroxyestr-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Norethandrolone
CA: CDSA Schedule IV Section 23 Subsection 31 Norethandrolone
UK: MDA Part III Class C Section 1(b) Norethandrolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(54)
Normethandrolone (17α-Methyl-17β-hydroxyestr-4-en-3-one)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(55)
Oxandrolone (17α-Methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Oxandrolone
CA: CDSA Schedule IV Section 23 Subsection 33 Oxandrolone
UK: MDA Part III Class C Section 1(b) Oxandrolone
⇒
PubChem: 5878; ChemSpider: 5667; Bluelight: Oxandrolone; Drugs Forum: Oxandrolone; Erowid: Steroids; Wikipedia: Oxandrolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(56)
Oxymesterone (17α-Methyl-4,17β-dihydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Oxymesterone
CA: CDSA Schedule IV Section 23 Subsection 34 Oxymesterone
UK: MDA Part III Class C Section 1(b) Oxymesterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(57)
Oxymetholone (17α-Methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Oxymetholone
CA: CDSA Schedule IV Section 23 Subsection 35 Oxymetholone
UK: MDA Part III Class C Section 1(b) Oxymetholone
⇒
PubChem: 3032303; ChemSpider: 4444502; Bluelight: Oxymetholone; Erowid: Steroids; Wikipedia: Oxymetholone
Prostanozol
Prostanozol, O-tetrahydropyran-2-yl
Effective 29 Aug 2012, 77 FR 44456 added (and renumbered subsequent entries):
On 23 Nov 2011, 76 FR 72355 proposed to add (and to renumber subsequent entries):
(58)
Prostanozol (17β-Hydroxy-5α-androstano[3,2-c]pyrazole)
[There is much confusion surrounding the name Prostanozol. The culprit seems to be the World Anti-Doping Agency (WADA), which every year updates their list of Prohibited Substances.
For 2009 (and later) it reads:
Prostanozol (17β-Hydroxy-5α-androstano[3,2-c]pyrazole), depicted at left, above.
For 2008 (and earlier) it reads:
Prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol), depicted at left, below.
Given these names describe distinctly different substances WADA’s explanation—“The nomenclature of Prostanozol has been changed to better follow the International Union of Pure and Applied Chemistry (IUPAC) rules”—has a certain… CYA quality. Not very helpful WADA. Definitely not very sporting.]
For 2009 (and later) it reads:
Prostanozol (17β-Hydroxy-5α-androstano[3,2-c]pyrazole), depicted at left, above.
For 2008 (and earlier) it reads:
Prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol), depicted at left, below.
Given these names describe distinctly different substances WADA’s explanation—“The nomenclature of Prostanozol has been changed to better follow the International Union of Pure and Applied Chemistry (IUPAC) rules”—has a certain… CYA quality. Not very helpful WADA. Definitely not very sporting.]
UK: MDA Part III Class C Section 1(b) Prostanozol
See also CSA Schedule III Section f Subsection 1 Item 89 [3,2-c]Pyrazole-5α-androstan-17β-ol
UK: MDA Part III Class C Section 1(b) Prostanozol, O-tetrahydropyran-2-yl
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Stanolone
Stanolone is a synonym for 4-Dihydrotestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(59)
Stanozolol (17α-Methyl-17β-hydroxy-[5α]-androst-2-eno[3,2-c]pyrazole)
Effective 13 Oct 2006, 71 FR 60426 replacement for:
Stanozolol (17α-Methyl-17α-hydroxy-[5α]-androst-2-eno[3,2-c]pyrazole)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Stanozolol
CA: CDSA Schedule IV Section 23 Subsection 38 Stanozolol
UK: MDA Part III Class C Section 1(b) Stanozolol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(60)
Stenbolone (17β-Hydroxy-2-methyl-[5α]-androst-1-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 39 Stenbolone
UK: MDA Part III Class C Section 1(b) Stenbolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(61)
Testolactone (13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Testolactone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(62)
Testosterone (17β-Hydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Testosterone
CA: CDSA Schedule IV Section 23 Subsection 40 Testosterone
UK: MDA Part III Class C Section 1(b) Testosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(63)
Tetrahydrogestrinone (13β,17α-Diethyl-17β-hydroxygon-4,9,11-trien-3-one)
UK: MDA Part III Class C Section 1(b) Tetrahydrogestrinone
⇒
PubChem: 25320811 6857686; ChemSpider: 5257020; Bluelight: Tetrahydrogestrinone; Erowid: Steroids; Wikipedia: Tetrahydrogestrinone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(64)
Trenbolone (17β-Hydroxyestr-4,9,11-trien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Trenbolone and
[With thanks to Jan of Palo Alto for reporting an error in the structural diagram shown previously for this substance.]
CA: CDSA Schedule IV Section 23 Subsection 43 Trenbolone
UK: MDA Part III Class C Section 1(b) Trenbolone
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(65)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(67)
6-Bromo-androsta-1,4-diene-3,17-dione
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(68)
4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
See also CSA Schedule III Section f Subsection 1 Item 72 4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(69)
4-Chloro-17α-methyl-androst-4-ene-3β,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(70)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(71)
4-Chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(72)
4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
See also CSA Schedule III Section f Subsection 1 Item 68 4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(73)
2α,17α-Dimethyl-17β-hydroxy-5α-androstan-3-one
See also CSA Schedule III Section f Subsection 1 Item 32 Methasterone
⇒
PubChem: 237186; ChemSpider: 207079; Bluelight: Superdrol; Erowid: Steroids; Wikipedia: Methasterone
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(74)
2α,17α-Dimethyl-17β-hydroxy-5β-androstan-3-one
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(75)
![3D rendering of [3,2-c]-Furazan-5α-androstan-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of [3,2-c]-Furazan-5α-androstan-17β-ol")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(76)
[3,2-c]-Furazan-5α-androstan-17β-ol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(77)
3β-Hydroxy-estra-4,9,11-trien-17-one
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(78)
17α-Methyl-androst-2-ene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(79)
17α-Methyl-androsta-1,4-diene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(80)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(81)
18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(82)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(83)
17α-Methyl-androstan-3-hydroxyimine-17β-ol
![3D rendering of 17β-Hydroxy-androstano[2,3-d]isoxazole](data:image/png;base64,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 "Click for a 3D rendering of 17β-Hydroxy-androstano[2,3-d]isoxazole")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(85)
17β-Hydroxy-androstano[2,3-d]isoxazole
![3D rendering of 17β-Hydroxy-androstano[3,2-c]isoxazole](data:image/png;base64,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 "Click for a 3D rendering of 17β-Hydroxy-androstano[3,2-c]isoxazole")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(86)
17β-Hydroxy-androstano[3,2-c]isoxazole
![3D rendering of 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(87)
4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol [sic]
![3D rendering of [3,2-c]Pyrazole-androst-4-en-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of [3,2-c]Pyrazole-androst-4-en-17β-ol")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(88)
[3,2-c]Pyrazole-androst-4-en-17β-ol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(89)
[3,2-c]Pyrazole-5α-androstan-17β-ol
UK: MDA Part III Class C Section 1(b) Prostanozol
See also CSA Schedule III Section f Subsection 1 Item 58 Prostanozol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. renumbered:
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(90)
Any salt, ester, or ether of a drug or substance described in this paragraph. Except such term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph.
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph.
Effective 2 Jul 1999, 64 FR 35928 added:
On 5 Nov 1998, 63 FR 59751 proposed to add:
(g)
Hallucinogenic substances.
Effective 2 Jul 1999, 64 FR 35928 added:
On 5 Nov 1998, 63 FR 59751 proposed to add:
(1)
7369
Dronabinol ((6aR-trans)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; (–)-Delta-9-(trans)-tetrahydrocannabinol) (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved product
UN: Psychotropics Schedule II Dronabinol (delta-9-Tetrahydrocannabinol)
Schedule IV [21 CFR 1308.14]
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Source: DEA Office of Diversion Control: Section 1308: Schedules of Controlled Substances
Effective 27 Sep 1978, 43 FR 38382 renumbered:
(b)
Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
Difenoxin
Atropine sulfate
Effective 27 Sep 1978, 43 FR 38382 added:
(1)
9167
Not more than 1 milligram of Difenoxin and not less than 25 micrograms of Atropine sulfate per dosage unit
See also CSA Schedule I Section b Subsection 20 Difenoxin and Schedule V Section c Subsection 6 Difenoxin
UN: Narcotics Part 2 Section 5 Atropine sulfate and Section 6 Atropine sulfate
See also CSA Schedule V Section c Subsection 4 Atropine sulfate and Subsection 6 Atropine sulfate
Effective 24 Jul 1980, 45 FR 42264 added:
(2)
9278
Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane)
CA: CDSA Schedule I Section 7 Subsection 3 Dextropropoxyphene
UK: MDA Part III Class C Section 1(a) Dextropropoxyphene
UN: Narcotics Part 1 Section 2 Dextropropoxyphene and Part 2 Section 3 Dextropropoxyphene
See also CSA Schedule II Section c Subsection 5 Dextropropoxyphene
![3D rendering of 2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAMcAAACjCAIAAACxAp3dAAAACXBIWXMAAC4jAAAuIwF4pT92AAAAHXRFWHRTb2Z0d2FyZQBHUEwgR2hvc3RzY3JpcHQgOC43MQM/aDQAAAhQSURBVHic7d2xjtNKFAbg46tb0M5uA63zBMh5AIrsCyBlJQT15BHsR0gaqB2JByBbIErkLSkdVtTIkegowJZ4gbnFLL5ZJ/E69pkZx/k/3YLNhdjZ/XM88cZ/PKUUAbD6x/UOwAAhVcAPqQJ+SBXwQ6qAH1IF/JAq4IdUAT+kCvghVcAPqQJ+SBXwQ6qAH1IF/JAq4IdUAT+kCvghVcAPqQJ+SBXwQ6rurdfr0Wi0WCwsb7coiiiKRqOR5e2apeCvMAyJyPf9JEnsbDGOY9/3hRBhGNrZoh1I1QNZlk0mEyKaTqdZlpnbUJqmekNSyjzPzW3ICaRqjyRJfN8nojAM2X/keZ5LKYloMpmkacp75z2BVB0UhqEQwvf9OI657nM+n7PfZw8hVXUY54rR+dc3SNXjOq6BrK3V+gOpaqrF67U8z+2/ruwDpOoI2yn59euXUopIBYGqzC99uubu7k4IIYSYz+cudtYlnAU9go5IlmVBENzd3ZW3R9Gev/z582cpZZZlOohnxVNoGmrl9+/fl5eXnkdpSuMxxTFJef+/PI+Uop8/fz59+tTpPjqDVHWiA7RY0GJBSUJB8P+N5wyp6qQM0NUVFQUlCQmBVOG3y0xWK9ps9i+wztC/rndgIISgOKbra/J917vSAzgCdlI52EUR6bfSnPk3FanqpJKqoqCrK1qvkaoz/waAAVit8/j69ev3799d70VfIFU8wjB8//69673oC6QK+CFVwA+pAn5IFfBDqoAfUgX8kCrgh1QBP6QK+CFVwA+pAn5IFfBDqoAfUgX8kCrgh1QBP6SKx48fPz58+HB7e2t5u7pW1PO8KIqKorC89YNcljwMyKdPn168eEFEulvBzkZ1x5quqelV2RpSxWm1Wtlpj93tWOtVMSRSxUy3EenJsVqt2O+/vmOtJyW2SJURWZZNp1M9ObgOiGV7VhAE9R1rzgu3kSqDkiQJgoA4ukDLJVTDlZPbmj+kyrg4jo8KREWXmloTI7MJpMqG5gevbVyZsF+fjFTZUy60Hz37YOL4dewxtAukyrbtsw97J0d5xGSvqS3DOplMjC62kCo39p59YFzd17Bw9gGpcibLsvK85Wq1srysNnrCFqlyLEkSPTnsnwIoT9hKKXnvGf1VveB5Xhkvy6IoWq/XSZIw3ifeswD8kCrgh1QBP6QK+CFVwA+pAn5IFfBDqoAfUgX8kCrgh1QBP6QK+CFVwA+pAn5IFfBDqoAfUgX8kCrg149UFQXNZnRxQZ5HFxc0m1F/qpjgeD1IVVHQaERCUJqSUpSmJASNRgjW6frX9Q4QRRFJSfP5/Ze+f//nKKI4drhf0FoPZtXNDUlZvVFKurlxsTfAoAepKgry/eqNvm/zCLjZbK6vry8uLhaLhbWNarrYk4jevXtnv9jz9vbWSJcp7+WFbQihdq/WzTIlhIWNb/dk2C98KisViOjZs2c2e8y2r5xmb3zsQaqkVLvfyjBU3BfU7tqtSbFW+FSpVCCijx8/2imN3X4imeiYVA5Tlef527dv9Z+UECoM7ydWlqkwVEKoPFdKffnyxcTk0C0DdKAnw2iLxt7gEpF+mNsjxMQDL6ej0aHoJlX6SfnmzZv7r/NcSamEUERKCCWl+vuz/PbtG+/kKBtRKm2tSZJUAsT+A6hppSpTVdlJxp7t8qlioYjWdqq2i1D//PnT5J9wTY76MRAEwW6AGA8W9a1UlVRp9QO1Ofs9jvZSVbZTtHv+dekK226rPrRkqWm03v6ptFjYNnlW7E2V1qUjz1XnrI1Ucb3caPc92p6Ojz7ja+bZ9rOi4eRoPiRqUqU6PHBDnX2PMpsqEy83mk+OFjnY/YeVNDSsMj82B/Wp0spa0Uczaqezr4bBVBl9rtSvPTses7RDQ+7RT39o8cCbpEpr/sBtVmFXGEmVtSrm3Zdp7CuJQwuyvYf11g+8eao0Cw+8C+ZU1X/Kignbk+P169cmpuP2Bw8dWmy9evVKf+ZWuyFxbKrUwweu/+BkCbUXc6rCMDyqqJ5LlmUvX740Oh1rziHFcfzkyZPLy8vWD7xFqrRyZLpaQu3Vg9/YMNHNluWXhj7N7NA5pMlk0uVkaetU9VMP3rNgxng8NvHbeH1kD8NwuVyORqMbvF1nn8Gmyqj5fK4PPfY/Evck9OC9oKdJL41d70VPYVYBP6SqF5Ikef78ueu9YIMjYC84+VQIczCrnKq/ENLzqn9/95ZeQqrcGe6FkDgCujPcCyExq9wZ7oWQmFXuNLkQ8kQWUhWYVe4IQZtN9cbNhoT4/0ulHvx3IpAqd6ZTWi6rNy6XNJ262BtOOAK6M5/TaEREJCX5Pm02tFzScklZ5nrPusKsckcIyjIqChqPyfNoPKaioCx7cAQ8TZhVTglBcXzwPMLuQupEllaYVcAPqQJ+SBXwQ6paWq/XV1dX4/HY9Y70EVJ1tKIoZrOZzlN84r+wM2SwrwHTNNXX+PKKomi5XOouDbn7WzzQXF/kwyZNUzLTR6gdui65vGi4J1d49sFwUqWMFX/VXJDtsHelzwaVKo3xJ13Ood0Lsp33rvTZAFOlmKosDqXTaPvvMAwzVVrr2p2aOVTfMQTakFOlHXWoqplDumGhYWffmRt+qrQmi62aXlD2RuFhO5dUqccWW/Udxk7qk07XGaVKO3SaII7jyhzqUh585s4uVVp91SLOGnR0pqnSHH6OzbCddarUw5UTzhpw8dSJvGnVqM1mM5vN1uu1lBKtVN0hVcAP768CfkgV8EOqgB9SBfyQKuCHVAE/pAr4IVXAD6kCfkgV8EOqgB9SBfyQKuCHVAE/pAr4IVXAD6kCfkgV8EOqgB9SBfz+A1vXOCz0RQIyAAAAAElFTkSuQmCC "Click for a 3D rendering of 2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol")
Effective 14 Aug 2014, 79 FR 37623 added:
(3)
9752
2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including Tramadol)
On 4 Nov 2013, 78 FR 65923 proposed to add:
Tramadol (2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol), its salts, optical and geometric isomers and salts of these isomers(c)
Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
On 25 Mar 2013, 78 FR 17895 proposed to add (and to renumber subsequent entries):
5α-Pregnan-3α-ol-11,20-dione (Alfaxalone)Effective 31 Mar 2014, 79 FR 10985 added (and renumbered subsequent entries):
(1)
2731
Alfaxalone
Effective 12 Nov 1981, 46 FR 55688 added (and renumbered subsequent entries):
(2)
2882
Alprazolam
CA: CDSA Schedule IV Section 18 Subsection 1 Alprazolam
UK: MDA Part III Class C Section 1(a) Alprazolam
UN: Psychotropics Schedule IV Alprazolam
⇒
PubChem: 2118; ChemSpider: 2034; Bluelight: Alprazolam; Drugs Forum: Alprazolam; Erowid: Alprazolam; Wikipedia: Alprazolam
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(4)
2748
Bromazepam
CA: CDSA Schedule IV Section 18 Subsection 2 Bromazepam
UK: MDA Part III Class C Section 1(a) Bromazepam
UN: Psychotropics Schedule IV Bromazepam
⇒
PubChem: 2441; ChemSpider: 2347; Drugs Forum: Bromazepam; Erowid: Bromazepam; Wikipedia: Bromazepam
Effective 11 Jan 2012, 76 FR 77329 added (and renumbered subsequent entries):
Effective 26 Mar 2010, 75 FR 14538 announced a hearing with respect to the proposed placement of Carisoprodol in schedule IV proposed in 74 FR 59108
On 17 Nov 2009, 74 FR 59108 proposed to add (and to renumber subsequent entries):
(6)
8192
Carisoprodol
(8)
2465
Chloral hydrate
⇒
PubChem: 2707; ChemSpider: 2606; Drugs Forum: Chloral Hydrate; Erowid: Chloral hydrate; Wikipedia: Chloral hydrate
Effective 2 Jul 1975, 40 FR 23998 added (and renumbered subsequent entries):
On 27 Jan 1975, 40 FR 4016 proposed to add (and to renumber subsequent entries):
(9)
2744
Chlordiazepoxide
CA: CDSA Schedule IV Section 18 Subsection 4 Chlordiazepoxide
UK: MDA Part III Class C Section 1(a) Chlordiazepoxide
UN: Psychotropics Schedule IV Chlordiazepoxide
⇒
PubChem: 2712; ChemSpider: 10248513; Drugs Forum: Chlordiazepoxide; Erowid: Chlordiazepoxide; Wikipedia: Chlordiazepoxide
Effective 2 Jul 1975, 40 FR 23998 added (and renumbered subsequent entries):
On 27 Jan 1975, 40 FR 4016 proposed to add (and to renumber subsequent entries):
(11)
2737
Clonazepam
CA: CDSA Schedule IV Section 18 Subsection 6 Clonazepam
UK: MDA Part III Class C Section 1(a) Clonazepam
UN: Psychotropics Schedule IV Clonazepam
⇒
PubChem: 2802; ChemSpider: 2700; Bluelight: Clonazepam; Drugs Forum: Clonazepam; Erowid: Clonazepam; Wikipedia: Clonazepam
Effective 2 Jul 1975, 40 FR 23998 added (and renumbered subsequent entries):
On 27 Jan 1975, 40 FR 4016 proposed to add (and to renumber subsequent entries):
(12)
2768
Clorazepate
CA: CDSA Schedule IV Section 18 Subsection 7 Clorazepate
UK: MDA Part III Class C Section 1(a) Clorazepic acid
UN: Psychotropics Schedule IV Clorazepate
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(13)
2752
Clotiazepam
CA: CDSA Schedule IV Section 12 Clotiazepam
UK: MDA Part III Class C Section 1(a) Clotiazepam
UN: Psychotropics Schedule IV Clotiazepam
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(14)
2753
Cloxazolam
CA: CDSA Schedule IV Section 18 Subsection 8 Cloxazolam
UK: MDA Part III Class C Section 1(a) Cloxazolam
UN: Psychotropics Schedule IV Cloxazolam
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(15)
2754
Delorazepam
CA: CDSA Schedule IV Section 18 Subsection 9 Delorazepam
UK: MDA Part III Class C Section 1(a) Delorazepam
UN: Psychotropics Schedule IV Delorazepam
Effective 2 Jul 1975, 40 FR 23998 added (and renumbered subsequent entries):
On 27 Jan 1975, 40 FR 4016 proposed to add (and to renumber subsequent entries):
(16)
2765
Effective 16 Aug 2001, 66 FR 42943 added (and renumbered subsequent entries):
On 11 Dec 2000, 65 FR 77328 proposed to add (and to renumber subsequent entries):
(17)
2467
Dichloralphenazone
(19)
2540
Ethchlorvynol
CA: CDSA Schedule IV Section 13 Ethchlorvynol
UK: MDA Part III Class C Section 1(a) Ethchlorvynol
UN: Psychotropics Schedule IV Ethchlorvynol
(20)
2545
Ethinamate
[With thanks to Noel at NIH/NCGC for noticing this entry was botched.]
CA: CDSA Schedule IV Section 14 Ethinamate
UK: MDA Part III Class C Section 1(a) Ethinamate
UN: Psychotropics Schedule IV Ethinamate
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(21)
2758
Ethyl loflazepate
CA: CDSA Schedule IV Section 18 Subsection 12 Ethyl loflazepate
UK: MDA Part III Class C Section 1(a) Ethyl loflazepate
UN: Psychotropics Schedule IV Ethyl loflazepate
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(22)
2759
Fludiazepam
CA: CDSA Schedule IV Section 18 Subsection 13 Fludiazepam
UK: MDA Part III Class C Section 1(a) Fludiazepam
UN: Psychotropics Schedule IV Fludiazepam
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(23)
2763
Flunitrazepam
CA: CDSA Schedule I Section 20 Flunitrazepam
CA: [revoked] CDSA Schedule III Section 25 Flunitrazepam
UK: MDA Part III Class C Section 1(a) Flunitrazepam
UN: Psychotropics Schedule III Flunitrazepam
⇒
PubChem: 3380; ChemSpider: 3263; Drugs Forum: Flunitrazepam; Erowid: Flunitrazepam; Wikipedia: Flunitrazepam
Effective 2 Jul 1975, 40 FR 23998 added (and renumbered subsequent entries):
On 27 Jan 1975, 40 FR 4016 proposed to add (and to renumber subsequent entries):
(24)
2767
Flurazepam
CA: CDSA Schedule IV Section 18 Subsection 15 Flurazepam
UK: MDA Part III Class C Section 1(a) Flurazepam
UN: Psychotropics Schedule IV Flurazepam
Effective 6 Oct 2009, 74 FR 51234 added (and renumbered subsequent entries):
On 23 Jul 2009, 74 FR 36424 proposed to add (and to renumber subsequent entries):
(25)
2138
Fospropofol
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(27)
2771
Haloxazolam
CA: CDSA Schedule IV Section 18 Subsection 17 Haloxazolam
UK: MDA Part III Class C Section 1(a) Haloxazolam
UN: Psychotropics Schedule IV Haloxazolam
On 31 Jan 2008, 73 FR 5778 proposed to add (and to renumber subsequent entries):
2726
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(29)
2773
Loprazolam
CA: CDSA Schedule IV Section 18 Subsection 19 Loprazolam
UK: MDA Part III Class C Section 1(a) Loprazolam
UN: Psychotropics Schedule IV Loprazolam
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(31)
2774
Lormetazepam
CA: CDSA Schedule IV Section 18 Subsection 21 Lormetazepam
UK: MDA Part III Class C Section 1(a) Lormetazepam
UN: Psychotropics Schedule IV Lormetazepam
Effective 30 Jan 1975, 40 FR 4418 added (and renumbered subsequent entries):
On 13 Dec 1974, 39 FR 43408 proposed to add (and to renumber subsequent entries):
(32)
2800
Mebutamate
(34)
2820
Meprobamate
CA: CDSA Schedule IV Section 16 Meprobamate
UK: MDA Part III Class C Section 1(a) Meprobamate
UN: Psychotropics Schedule IV Meprobamate
(36)
2250
Methylphenobarbital (Mephobarbital)
CA: CDSA Schedule IV Section 1 Subsection 16 Mephobarbital
⇒
PubChem: 8271; ChemSpider: 7972; Bluelight: Methylphenobarbital; Erowid: Barbiturates; Wikipedia: Methylphenobarbital
Effective 25 Mar 1986, 51 FR 10190 added (and renumbered subsequent entries):
(37)
2884
Midazolam
[With thanks to Noel at NIH/NCGC for noticing this entry was botched.]
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(38)
2837
Nimetazepam
CA: CDSA Schedule IV Section 18 Subsection 23 Nimetazepam
UK: MDA Part III Class C Section 1(a) Nimetazepam
UN: Psychotropics Schedule IV Nimetazepam
⇒
PubChem: 4496; ChemSpider: 4340; Drugs Forum: Nimetazepam; Erowid: Nimetazepam; Wikipedia: Nimetazepam
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(39)
2834
Nitrazepam
CA: CDSA Schedule IV Section 18 Subsection 24 Nitrazepam
UK: MDA Part III Class C Section 1(a) Nitrazepam
UN: Psychotropics Schedule IV Nitrazepam
⇒
PubChem: 4506; ChemSpider: 4350; Drugs Forum: Nitrazepam; Erowid: Nitrazepam Synthesis; Wikipedia: Nitrazepam
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(40)
2838
Nordiazepam
CA: CDSA Schedule IV Section 18 Subsection 25 Nordazepam
UK: MDA Part III Class C Section 1(a) Nordazepam
UN: Psychotropics Schedule IV Nordazepam
⇒
PubChem: 2997; ChemSpider: 2890; Bluelight: Nordiazepam ; Erowid: Nordiazepam Synthesis; Wikipedia: Nordazepam
Effective 2 Jul 1975, 40 FR 23998 added (and renumbered subsequent entries):
On 27 Jan 1975, 40 FR 4016 proposed to add (and to renumber subsequent entries):
(41)
2835
(43)
2585
Paraldehyde
⇒
PubChem: 31264; ChemSpider: 21106173; Bluelight: Paraldehyde ; Erowid: Paraldehyde Synthesis; Wikipedia: Paraldehyde
(45)
2285
Phenobarbital
CA: CDSA Schedule IV Section 1 Subsection 21 Phenobarbital
UN: Psychotropics Schedule IV Phenobarbital
⇒
PubChem: 4763; ChemSpider: 4599; Bluelight: Phenobarbital vs. benzo's; Drugs Forum: Phenobarbital; Erowid: Barbiturates; Wikipedia: Phenobarbital
Effective 29 Sep 2014, 79 FR 51243 added (and renumbered subsequent entries):
On 13 Feb 2014, 79 FR 8639 proposed to add (and to renumber subsequent entries):
(49)
2223
Suvorexant
Effective 5 Nov 1984, 49 FR 39307 added (and renumbered subsequent entries):
(51)
2886
Tetrazepam
CA: CDSA Schedule IV Section 18 Subsection 31 Tetrazepam
UK: MDA Part III Class C Section 1(a) Tetrazepam
UN: Psychotropics Schedule IV Tetrazepam
⇒
PubChem: 25215; ChemSpider: 23551; Bluelight: Tetrazepam; Drugs Forum: Tetrazepam; Wikipedia: Tetrazepam
Effective 15 May 2003, 68 FR 26247 withdrew the prior proposed rule.
On 6 May 1997, 62 FR 24620 proposed to revoke:
Effective 15 Jun 1973, 38 FR 15719 added:
(d)
Fenfluramine. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12123 proposed to add:
(1)
1670
Fenfluramine
Effective 7 Jun 2013, 78 FR 26701 added (and renumbered subsequent entries):
On 19 Dec 2012, 77 FR 75075 proposed to add (and to renumber subsequent entries):
(e)
Lorcaserin. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
Effective 7 Jun 2013, 78 FR 26701 added:
On 19 Dec 2012, 77 FR 75075 proposed to add:
(1)
1625
Lorcaserin
⇒
PubChem: 11658860; ChemSpider: 9833595; Bluelight: Lorcaserin; Erowid: Lorcaserin; Wikipedia: Lorcaserin(f)
Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:
Effective 31 Dec 1969, replacement for:
Effective 6 Jul 1973, 38 FR 18013 added:
Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of isomers whenever the existance of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
Effective 6 Jul 1973, 38 FR 18013 added:
(2)
1610
Diethylpropion
CA: CDSA Schedule IV Section 4 Diethylpropion
UK: MDA Part II Class B Section 1(aa) Diethylpropion and Part III Class C Section 1(a) Diethylpropion
UN: Psychotropics Schedule IV Amfepramone (Diethylpropion)
Effective 16 Jun 1988, 53 FR 17459 added (and renumbered subsequent entries):
(3)
1760
Fencamfamin
CA: CDSA Schedule IV Section 20 Fencamfamin
UK: MDA Part III Class C Section 1(a) Fencamfamin
UN: Psychotropics Schedule IV Fencamfamin
Effective 16 Jun 1988, 53 FR 17459 added (and renumbered subsequent entries):
(4)
1575
Fenproporex
CA: CDSA Schedule IV Section 21 Fenproporex
UK: MDA Part III Class C Section 1(a) Fenproporex
UN: Psychotropics Schedule IV Fenproporex
Effective 28 Jan 1975, 40 FR 4150 added:
On 7 Nov 1974, 39 FR 39451 proposed to add:
(8)
1530
Pemoline (including organometallic complexes and chelates thereof)
Effective 6 Jul 1973, 38 FR 18013 added:
(9)
1640
Phentermine
CA: CDSA Schedule IV Section 8 Phentermine
UK: MDA Part III Class C Section 1(a) Phentermine
UN: Psychotropics Schedule IV Phentermine
Effective 11 Feb 1998, 63 FR 6862 added:
On 8 Dec 1997, 62 FR 64526 proposed to add:
(11)
1675
Sibutramine
⇒
PubChem: 5210; ChemSpider: 5021; Bluelight: Sibutramine (amphetamines); Drugs Forum: Sibutramine addiction; Wikipedia: Sibutramine
Effective 1 Dec 1980, 45 FR 64570 added:
(12)
1635
SPA ((–)-1-Dimethylamino-1,2-diphenylethane)
CA: CDSA Schedule III Section 29 Lefetamine
UK: MDA Part II Class B Section 1(a) Lefetamine
UN: Psychotropics Schedule IV Lefetamine (SPA)
⇒
PubChem: 22779; ChemSpider: 21356; Bluelight: Lefetamine; Drugs Forum: Lefetamine; Wikipedia: LefetamineEffective 14 Mar 1977, 42 FR 8636 added:
(g)
Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:
Effective 14 Mar 1977, 42 FR 8636 added:
8121
Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane)
US: Currently at CSA Schedule IV Section b Subsection 2 Dextropropoxyphene
Effective 9 Feb 1979, 44 FR 2169 added:
(1)
9709
Pentazocine
CA: CDSA Schedule I Section 11 Subsection 3 Pentazocine
⇒
PubChem: 4736; ChemSpider: 390041; Bluelight: Pentazocine; Drugs Forum: Pentazocine; Wikipedia: Pentazocine
Effective 31 Oct 1997, 62 FR 51370 added:
On 10 Jul 1997, 62 FR 37004 proposed to add:
(2)
9720
Butorphanol (including its optical isomers)
CA: CDSA Schedule IV Section 9 Butorphanol
Effective 17 Dec 2015, 80 FR 70680 corrected rule 80 FR 69861 by moving the effective date to 14 Dec 2015 from 17 Dec 2015
Effective 14 Dec 2015, 80 FR 69861 added:
On 11 Aug 2015, 80 FR 48044 proposed to add:
(3)
9725
Schedule V [21 CFR 1308.15]
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Source: DEA Office of Diversion Control: Section 1308: Schedules of Controlled Substances
Effective 1 Apr 1985, 50 FR 8104 added:
(b)
Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs and their salts, as set forth below:
(1)
[Reserved]
Effective 7 Oct 2002, 67 FR 62354 replacement for:
On 21 Mar 2002, 67 FR 13114 proposed replacement for:
Effective 1 Apr 1985, 50 FR 8104 added:
Buprenorphine
US: Currently at CSA Schedule III Section e Subsection 2 Item i Buprenorphine
Effective 1 Apr 1985, 50 FR 8104 renumbered:
(c)
Narcotic drugs containing non-narcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:
(1)
Not more than 200 milligrams of Codeine per 100 milliliters or per 100 grams.
(2)
Not more than 100 milligrams of Dihydrocodeine per 100 milliliters or per 100 grams.
CA: CDSA Schedule I Section 1 Subsection 11 Dihydrocodeine
UK: MDA Part II Class B Section 1(a) Dihydrocodeine
UN: Narcotics Part 1 Section 2 Dihydrocodeine and Part 2 Section 1 Dihydrocodeine
See also CSA Schedule II Section c Subsection 7 Dihydrocodeine and Schedule III Section e Subsection 1 Item iii Dihydrocodeine
(3)
Not more than 100 milligrams of Ethylmorphine per 100 milliliters or per 100 grams.
CA: CDSA Schedule I Section 1 Subsection 13 Ethylmorphine
UK: MDA Part II Class B Section 1(a) Ethylmorphine
UN: Narcotics Part 1 Section 2 Ethylmorphine and Part 2 Section 1 Ethylmorphine
See also CSA Schedule II Section b Subsection 1 Item iii Ethylmorphine and Schedule III Section e Subsection 1 Item iv Ethylmorphine
Diphenoxylate
Atropine sulfate
(4)
Not more than 2.5 milligrams of Diphenoxylate and not less than 25 micrograms of Atropine sulfate per dosage unit.
CA: CDSA Schedule I Section 3 Subsection 8 Diphenoxylate
UK: MDA Part I Class A Section 1(a) Diphenoxylate
UN: Narcotics Part 1 Section 1 Diphenoxylate and Part 2 Section 6 Diphenoxylate
See also CSA Schedule II Section c Subsection 8 Diphenoxylate
UN: Narcotics Part 2 Section 5 Atropine sulfate and Section 6 Atropine sulfate
See also CSA Schedule IV Section b Subsection 1 Atropine sulfate and Schedule V Section c Subsection 6 Atropine sulfate
(5)
Not more than 100 milligrams of Opium per 100 milliliters or per 100 grams.
See also CSA Schedule II Section b Subsection 1 Item xvi Raw opium, Schedule III Section e Subsection 1 Item i Opium and Item v Opium
⇒
PubChem: 167253 202889 202890 17397953 17397584 3842991 202886 202888 413265 3730541; Drugs Forum: Opium; Wikipedia: Opium
Difenoxin
Atropine sulfate
Effective 27 Sep 1978, 43 FR 38382 added:
(6)
Not more than 0.5 milligram of Difenoxin and not less than 25 micrograms of Atropine sulfate per dosage unit.
See also CSA Schedule I Section b Subsection 20 Difenoxin and Schedule IV Section b Subsection 1 Difenoxin
UN: Narcotics Part 2 Section 5 Atropine sulfate and Section 6 Atropine sulfate
See also CSA Schedule IV Section b Subsection 1 Atropine sulfate and Schedule V Section c Subsection 4 Atropine sulfate
Effective 4 May 1988, 53 FR 10869 added:
(d)
Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:
Effective 3 Dec 1991, 56 FR 61372 revoked:
Effective 4 May 1988, 53 FR 10869 added:
8161
Propylhexedrine
Effective 4 May 1988, 53 FR 10869 added:
(1)
1485
Pyrovalerone
CA: CDSA Schedule IV Section 26 Pyrovalerone
UK: MDA Part II Class B Section 1(aa) Pyrovalerone and Part III Class C Section 1(a) Pyrovalerone
UN: Psychotropics Schedule IV Pyrovalerone
Effective 28 Jul 2005, 70 FR 43633 added:
On 13 May 2005, 70 FR 25502 proposed to add:
(e)
Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:
Effective 15 Dec 2011, 76 FR 77895 added (and renumbered subsequent entries):
On 21 Oct 2011, 76 FR 65424 proposed to add (and to renumber subsequent entries):
(1)
2746
Ezogabine (N-[2-Amino-4-(4-fluorobenzylamino)phenyl]-carbamic acid ethyl ester)
Effective 22 Jun 2009, 74 FR 23789 added:
On 10 Mar 2009, 74 FR 10205 proposed to add:
(2)
2779
Lacosamide ((R)-2-Acetoamido-N-benzyl-3-methoxypropionamide)
Effective 28 Jul 2005, 70 FR 43633 added:
On 13 May 2005, 70 FR 25502 proposed to add:
(3)
2782
Pregabalin ((S)-3-(Aminomethyl)-5-methylhexanoic acid)
⇒
PubChem: 5486971; ChemSpider: 3902475; Bluelight: Pregabalin; Drugs Forum: Pregabalin; Erowid: Pregabalin; Wikipedia: PregabalinEffective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
Substances Covered [21 CFR 1310.02]
Source: DEA Office of Diversion Control: Section 1308: Schedules of Controlled Substances
(a)
List I chemicals
Effective 22 Jun 1995, 60 FR 32447 replacement for:
On 13 Oct 1994, 59 FR 51887 proposed replacement for:
On 8 Feb 1989, 54 FR 6144 proposed to add:
Listed Precursor Chemicals
Effective 1 Aug 1989, 54 FR 31657 added:
(1)
8530
Anthranilic acid, its esters, and its salts
Effective 22 Jun 1995, 60 FR 32447 replacement for:
On 13 Oct 1994, 59 FR 51887 proposed replacement for:
On 8 Feb 1989, 54 FR 6144 proposed to add:
Anthranilic acid and its salts
Effective 1 Aug 1989, 54 FR 31657 added:
CA: CDSA Schedule VI Part 1 Subsection 3 Anthranilic acid
EU: Drug precursors Annex I Category 2 Anthranilic acid and Annex II Anthranilic acid
UK: MDA Drug precursors Annex I Category 2 Anthranilic acid and Drug precursors Annex II Anthranilic acid
UN: Precursors Table II Anthranilic acid
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(2)
8735
Benzyl cyanide
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(3)
8113
Ephedrine, its salts, optical isomers, and salts of optical isomers
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(4)
8675
Ergonovine and its salts
CA: CDSA Schedule VI Part 1 Subsection 5 Ergometrine
EU: Drug precursors Annex I Category 1 Ergometrine
UK: MDA Drug precursors Annex I Category 1 Ergometrine
UN: Precursors Table I Ergometrine
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(5)
8676
Ergotamine and its salts
CA: CDSA Schedule VI Part 1 Subsection 6 Ergotamine
EU: Drug precursors Annex I Category 1 Ergotamine
UK: MDA Drug precursors Annex I Category 1 Ergotamine
UN: Precursors Table I Ergotamine
(6)
8522
N-Acetylanthranilic acid, its esters, and its salts
Effective 22 Jun 1995, 60 FR 32447 replacement for:
On 13 Oct 1994, 59 FR 51887 proposed replacement for:
On 8 Feb 1989, 54 FR 6144 proposed to add:
N-Acetylanthranilic acid and its salts
Effective 1 Aug 1989, 54 FR 31657 added:
CA: CDSA Schedule VI Part 1 Subsection 2 N-Acetylanthranilic acid
EU: Drug precursors Annex I Category 1 N-Acetylanthranilic acid
UK: MDA Drug precursors Annex I Category 1 N-Acetylanthranilic acid
UN: Precursors Table I N-Acetylanthranilic acid
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(7)
8317
Norpseudoephedrine, its salts, optical isomers, and salts of optical isomers
(8)
8791
Phenylacetic acid, its esters, and its salts
Effective 22 Jun 1995, 60 FR 32447 replacement for:
On 13 Oct 1994, 59 FR 51887 proposed replacement for:
On 8 Feb 1989, 54 FR 6144 proposed to add:
Phenylacetic acid and its salts
Effective 1 Aug 1989, 54 FR 31657 added:
CA: CDSA Schedule VI Part 1 Subsection 12 Phenylacetic acid
EU: Drug precursors Annex I Category 2 Phenylacetic acid and Annex II Phenylacetic acid
UK: MDA Drug precursors Annex I Category 2 Phenylacetic acid and Drug precursors Annex II Phenylacetic acid
UN: Precursors Table II Phenylacetic acid
⇒
PubChem: 999; ChemSpider: 10181341; Erowid: Phenylacetic acid synthesis; Wikipedia: Phenylacetic acid
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(9)
1225
Phenylpropanolamine, its salts, optical isomers, and salts of optical isomers
CA: CDSA Schedule VI Part 1 Subsection 10 Norephedrine
EU: Drug precursors Annex I Category 1 Norephedrine
UK: MDA Drug precursors Annex I Category 1 Norephedrine
UN: Precursors Table I Norephedrine
⇒
PubChem: 10297 26934; ChemSpider: 9875; Bluelight: Phenylpropanolamine; Erowid: Phenylpropanolamine; Wikipedia: Phenylpropanolamine
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(10)
2704
Piperidine and its salts
CA: CDSA Schedule VI Part 1 Subsection 13 Piperidine
EU: Drug precursors Annex I Category 2 Piperidine and Annex II Piperidine
UK: MDA Drug precursors Annex I Category 2 Piperidine and Drug precursors Annex II Piperidine
UN: Precursors Table II Piperidine
⇒
PubChem: 8082; ChemSpider: 7791; Drugs Forum: Piperidines; Erowid: Piperidine; Wikipedia: Piperidine
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(11)
8112
Pseudoephedrine, its salts, optical isomers, and salts of optical isomers
CA: CDSA Schedule VI Part 1 Subsection 16 Pseudoephedrine
EU: Drug precursors Annex I Category 1 Pseudoephedrine
UK: MDA Drug precursors Annex I Category 1 Pseudoephedrine
UN: Precursors Table I Pseudoephedrine
⇒
PubChem: 7028; ChemSpider: 6761; Bluelight: Pseudoephedrine; Drugs Forum: Pseudoephedrine; Erowid: Ephedrine; Wikipedia: Pseudoephedrine
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(12)
8502
3,4-Methylenedioxyphenyl-2-propanone
CA: CDSA Schedule VI Part 1 Subsection 9 3,4-Methylenedioxyphenyl-2-propanone
EU: Drug precursors Annex I Category 1 3,4-Methylenedioxyphenylpropan-2-one
UK: MDA Drug precursors Annex I Category 1 3,4-Methylenedioxyphenyl-2-propanone
UN: Precursors Table I 3,4-Methylenedioxyphenyl-2-propanone
Effective 26 Sep 1991, 56 FR 48732 added:
On 21 Jun 1991, 56 FR 27471 proposed to add:
(13)
8520
Methylamine and its salts
Effective 26 Sep 1991, 56 FR 48732 added:
On 21 Jun 1991, 56 FR 27471 proposed to add:
(14)
8678
Ethylamine and its salts
Effective 22 Jun 1995, 60 FR 32447 revoked (and renumbered subsequent entries):
On 13 Oct 1994, 59 FR 51887 proposed to revoke (and to renumber subsequent entries:)
Effective 26 Sep 1991, 56 FR 48732 added:
On 21 Jun 1991, 56 FR 27471 proposed to add:
D-Lysergic acid, its salts, optical isomers, and salts of optical isomers
US: Also at CSA Schedule III Section c Subsection 8 Lysergic acid
Effective 26 Sep 1991, 56 FR 48732 added:
On 21 Jun 1991, 56 FR 27471 proposed to add:
(15)
8328
Propionic anhydride
(16)
8704
Isosafrole
Effective 10 Feb 1997, 62 FR 5914 replacement for:
On 21 Jun 1991, 56 FR 27471 proposed to add:
Insosafrole[sic] (Isosafrole)
Effective 26 Sep 1991, 56 FR 48732 added:
CA: CDSA Schedule VI Part 1 Subsection 7 Isosafrole
EU: Drug precursors Annex I Category 1 Isosafrole
UK: MDA Drug precursors Annex I Category 1 Isosafrole
UN: Precursors Table I Isosafrole
Effective 26 Sep 1991, 56 FR 48732 added:
On 21 Jun 1991, 56 FR 27471 proposed to add:
(19)
8115
N-Methylephedrine, its salts, optical isomers, and salts of optical isomers (N-Methylephedrine)
Effective 22 Jun 1995, 60 FR 32447 revoked (and renumbered subsequent entries):
On 13 Oct 1994, 59 FR 51887 proposed to revoke (and to renumber subsequent entries:)
Effective 26 Sep 1991, 56 FR 48732 added:
On 21 Jun 1991, 56 FR 27471 proposed to add:
N-Ethylephedrine, its salts, optical isomers, and salts of optical isomers
Effective 26 Sep 1991, 56 FR 48732 added:
On 21 Jun 1991, 56 FR 27471 proposed to add:
(20)
8119
N-Methylpseudoephedrine, its salts, optical isomers, and salts of optical isomers
Effective 22 Jun 1995, 60 FR 32447 revoked (and renumbered subsequent entries):
On 13 Oct 1994, 59 FR 51887 proposed to revoke (and to renumber subsequent entries:)
Effective 26 Sep 1991, 56 FR 48732 added:
On 21 Jun 1991, 56 FR 27471 proposed to add:
N-Ethylpseudoephedrine, its salts, optical isomers, and salts of optical isomers
(21)
6695
Hydriodic acid
Effective 10 Feb 1997, 62 FR 5914 replacement for:
On 21 Jun 1991, 56 FR 27471 proposed to add:
Hydriotic acid[sic] (Hydriodic acid)
Effective 26 Sep 1991, 56 FR 48732 added:
CA: CDSA Schedule VI Part 1 Subsection 23 Hydriodic acid
Effective 22 Jun 1995, 60 FR 32447 added:
On 13 Oct 1994, 59 FR 51887 proposed to add:
(22)
8256
Benzaldehyde
Effective 22 Jun 1995, 60 FR 32447 added:
On 13 Oct 1994, 59 FR 51887 proposed to add:
(23)
6724
Nitroethane
Effective 24 Apr 2000, 65 FR 21645 added:
(24)
2011
Gamma-butyrolactone (GBL; Dihydro-2(3H)-furanone; 1,2-Butanolide; 1,4-Butanolide; 4-Hydroxybutanoic acid lactone; Gamma-hydroxybutyric acid lactone)
CA: CDSA Schedule VI Part 1 Subsection 18 Gamma-butyrolactone
UK: MDA Part III Class C Section 1(a) Gamma-butyrolactone
[Red phosphorus is one form of elemental phosphorus.]
Effective 17 Oct 2001, 66 FR 52670 added:
On 25 Sep 2000, 65 FR 57577 proposed to add:
On 2 Feb 2000, 65 FR 4913 proposed to add:
(25)
6795
Red phosphorus
CA: CDSA Schedule VI Part 1 Subsection 20 Red phosphorous
[White phosphorus (Yellow phosphorus) is one form of elemental phosphorus.]
Effective 17 Oct 2001, 66 FR 52670 added:
On 25 Sep 2000, 65 FR 57577 proposed to add:
(26)
6796
White phosphorus (Yellow phosphorus)
CA: CDSA Schedule VI Part 1 Subsection 21 White phosphorous
Effective 17 Oct 2001, 66 FR 52670 added:
On 25 Sep 2000, 65 FR 57577 proposed to add:
(27)
6797
Hypophosphorous acid and its salts (including ammonium hypophosphite, calcium hypophosphite, iron hypophosphite, potassium hypophosphite, manganese hypophosphite, magnesium hypophosphite and sodium hypophosphite)
CA: CDSA Schedule VI Part 1 Subsection 22 Hypophosphorous acid
Effective 25 Jul 2008, 73 FR 43355 finalized the prior interim scheduling:
Effective 23 Apr 2007, 72 FR 20039 added on an interim basis, with requests for comments:
(28)
8332
N-Phenylethyl-4-piperidone (NPP)
Effective 24 Jul 2007, 72 FR 40238 redesignated this entry as (29), correcting the original designation of (28)
Effective 2 Jul 2007, 72 FR 35920 added:
On 11 Aug 2006, 71 FR 46144 proposed to add:
(29)
6699
Effective 2 May 2011, 76 FR 17778 added:
On 24 Feb 2010, 75 FR 8287 proposed to add:
(30)
8612
Ergocristine and its salts
(b)
List II chemicals
Effective 22 Jun 1995, 60 FR 32447 replacement for:
On 13 Oct 1994, 59 FR 51887 proposed replacement for:
On 8 Feb 1989, 54 FR 6144 proposed to add:
Listed Essential Chemicals
Effective 1 Aug 1989, 54 FR 31657 added:
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(1)
8519
Acetic anhydride
CA: CDSA Schedule VI Part 1 Subsection 1 Acetic anhydride
EU: Drug precursors Annex I Category 2 Acetic anhydride and Annex II Acetic anhydride
UK: MDA Drug precursors Annex I Category 2 Acetic anhydride and Drug precursors Annex II Acetic anhydride
UN: Precursors Table I Acetic anhydride
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(3)
8570
Benzyl chloride
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(4)
6584
Ethyl ether
CA: CDSA Schedule VI Part 2 Subsection 2 Ethyl ether
EU: Drug precursors Annex I Category 3 Ethyl ether
UK: MDA Drug precursors Annex I Category 3 Ethyl ether
UN: Precursors Table II Ethyl ether
Effective 26 Sep 1991, 56 FR 48732 revoked (and renumbered subsequent entries):
On 21 Jun 1991, 56 FR 27471 proposed to revoke (and to renumber subsequent entries:)
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
6695
Hydriodic acid
US: Currently at CSA Listed Chemicals Section a Subsection 21 Hydriodic acid
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(5)
6579
Potassium permanganate
CA: CDSA Schedule VI Part 1 Subsection 15 Potassium permanganate
EU: Drug precursors Annex I Category 2 Potassium permanganate and Annex II Potassium permanganate
UK: MDA Drug precursors Annex I Category 2 Potassium permanganate and Drug precursors Annex II Potassium permanganate
UN: Precursors Table I Potassium permanganate
⇒
PubChem: 516875; ChemSpider: 22810; Bluelight: KMnO4 substitute; Wikipedia: Potassium permanganate
Effective 1 Aug 1989, 54 FR 31657 added:
On 8 Feb 1989, 54 FR 6144 proposed to add:
(6)
6714
2-Butanone (Methyl ethyl ketone; MEK)
CA: CDSA Schedule VI Part 2 Subsection 4 Methyl ethyl ketone
EU: Drug precursors Annex I Category 3 Methylethylketone
UK: MDA Drug precursors Annex I Category 3 Methyl ethyl ketone
UN: Precursors Table II Methyl ethyl ketone
(8)
6545
Hydrochloric acid (including anhydrous hydrogen chloride)
Effective 2 Aug 2000, 65 FR 47309 replacement for:
On 11 Dec 1991, 56 FR 64582 proposed to add:
Hydrochloric acid
Effective 22 Sep 1992, 57 FR 43614 added:
CA: CDSA Schedule VI Part 2 Subsection 3 Hydrochloric acid
EU: Drug precursors Annex I Category 3 Hydrochloric acid
UK: MDA Drug precursors Annex I Category 3 Hydrochloric acid
UN: Precursors Table II Hydrochloric acid
Effective 22 Sep 1992, 57 FR 43614 added:
On 11 Dec 1991, 56 FR 64582 proposed to add:
(9)
6552
Sulfuric acid
CA: CDSA Schedule VI Part 2 Subsection 5 Sulphuric acid
EU: Drug precursors Annex I Category 3 Sulphuric acid
UK: MDA Drug precursors Annex I Category 3 Sulphuric acid
UN: Precursors Table II Sulphuric acid
Effective 19 Apr 1995, 60 FR 19509 added:
On 28 Feb 1995, 60 FR 10814 proposed to add:
(10)
6715
Methyl isobutyl ketone (MIBK)
Effective 2 Jul 2007, 72 FR 35920 revoked (and renumbered subsequent entries):
On 11 Aug 2006, 71 FR 46144 proposed to revoke (and to renumber subsequent entries:)
Effective 2 Aug 2000, 65 FR 47309 added:
6699
Iodine
US: Currently at CSA Listed Chemicals Section a Subsection 29 Iodine
Effective 17 Oct 2006, 71 FR 60823 added:
On 1 Mar 2005, 70 FR 9889 proposed to add:
(11)
6588
Sodium permanganate
11 March 2016 · 
· Isomer Design
· Isomer Design